WO2019074089A1 - 高レバウジオシドm含有ステビア植物 - Google Patents
高レバウジオシドm含有ステビア植物 Download PDFInfo
- Publication number
- WO2019074089A1 WO2019074089A1 PCT/JP2018/038064 JP2018038064W WO2019074089A1 WO 2019074089 A1 WO2019074089 A1 WO 2019074089A1 JP 2018038064 W JP2018038064 W JP 2018038064W WO 2019074089 A1 WO2019074089 A1 WO 2019074089A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- rebaudioside
- plant
- base
- sequence
- Prior art date
Links
- GSGVXNMGMKBGQU-PHESRWQRSA-N rebaudioside M Chemical compound C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GSGVXNMGMKBGQU-PHESRWQRSA-N 0.000 title claims abstract description 186
- 244000228451 Stevia rebaudiana Species 0.000 title description 2
- 241000196324 Embryophyta Species 0.000 claims abstract description 181
- 241000544066 Stevia Species 0.000 claims abstract description 85
- 238000004519 manufacturing process Methods 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims description 151
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 claims description 108
- 108091008146 restriction endonucleases Proteins 0.000 claims description 77
- 108700028369 Alleles Proteins 0.000 claims description 74
- 230000002068 genetic effect Effects 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 41
- 235000019202 steviosides Nutrition 0.000 claims description 41
- 239000004383 Steviol glycoside Substances 0.000 claims description 40
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical class O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 40
- 235000019411 steviol glycoside Nutrition 0.000 claims description 40
- 229930182488 steviol glycoside Natural products 0.000 claims description 40
- 150000008144 steviol glycosides Chemical class 0.000 claims description 40
- 239000003550 marker Substances 0.000 claims description 39
- 238000012216 screening Methods 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 24
- 238000012408 PCR amplification Methods 0.000 claims description 21
- 235000013305 food Nutrition 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 5
- 210000001938 protoplast Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 235000019605 sweet taste sensations Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 description 85
- 239000002773 nucleotide Substances 0.000 description 55
- 125000003729 nucleotide group Chemical group 0.000 description 55
- 210000001519 tissue Anatomy 0.000 description 25
- 230000035772 mutation Effects 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 20
- 239000001512 FEMA 4601 Substances 0.000 description 20
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 20
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 20
- 235000019203 rebaudioside A Nutrition 0.000 description 20
- 238000001514 detection method Methods 0.000 description 18
- 229930188195 rebaudioside Natural products 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 6
- 229940032084 steviol Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000004226 microchip electrophoresis Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- QRGRAFPOLJOGRV-UHFFFAOYSA-N rebaudioside F Natural products CC12CCCC(C)(C1CCC34CC(=C)C(CCC23)(C4)OC5OC(CO)C(O)C(OC6OCC(O)C(O)C6O)C5OC7OC(CO)C(O)C(O)C7O)C(=O)OC8OC(CO)C(O)C(O)C8O QRGRAFPOLJOGRV-UHFFFAOYSA-N 0.000 description 4
- HYLAUKAHEAUVFE-AVBZULRRSA-N rebaudioside f Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HYLAUKAHEAUVFE-AVBZULRRSA-N 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 238000012225 targeting induced local lesions in genomes Methods 0.000 description 4
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- -1 RebA Chemical class 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011880 melting curve analysis Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000010152 pollination Effects 0.000 description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- QSIDJGUAAUSPMG-CULFPKEHSA-N steviolmonoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QSIDJGUAAUSPMG-CULFPKEHSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- DRSKVOAJKLUMCL-MMUIXFKXSA-N u2n4xkx7hp Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DRSKVOAJKLUMCL-MMUIXFKXSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108010061979 CEL I nuclease Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 description 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- OMHUCGDTACNQEX-OSHKXICASA-N Steviolbioside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OMHUCGDTACNQEX-OSHKXICASA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- HINSNOJRHFIMKB-DJDMUFINSA-N [(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate Chemical compound [H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC(=O)[C@]2(C)CCC[C@@]3(C)[C@]4([H])CC[C@@]5(C[C@]4(CC5=C)CC[C@]23[H])O[C@]2([H])O[C@H](CO)[C@@H](O)[C@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]2O[C@]2([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O HINSNOJRHFIMKB-DJDMUFINSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- JLPRGBMUVNVSKP-AHUXISJXSA-M chembl2368336 Chemical compound [Na+].O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C([O-])=O)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O JLPRGBMUVNVSKP-AHUXISJXSA-M 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010041758 cleavase Proteins 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/14—Asteraceae or Compositae, e.g. safflower, sunflower, artichoke or lettuce
- A01H6/1488—Stevia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/06—Roots
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/10—Seeds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/12—Leaves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/36—Terpene glycosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/04—Plant cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/13—Plant traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to Stevia plants having a high content of rebaudioside M.
- Patent Document 1 discloses a functional sweetener composition containing a vitamin, a high sweetness sweetener, and a sweet taste improving composition.
- Rebaudioside (Rebaudioside, hereinafter also referred to as "Reb") is known as a sweetening ingredient contained in stevia extract.
- Stevia extract is extracted and purified from Stevia leaves.
- Stevia is a chrysanthemum perennial plant originating in South America Paraguay, and its scientific name is Stevia Rebaudiana Bertoni. Since Stevia contains a component having a sweetness of about 300 times or more that of sugar, it is cultivated to extract this sweet component and use it as a natural sweetener.
- As Reb the existence of various glycosides such as RebA, RebB, RebC, RebD, RebE, RebM, etc. has been reported (Japanese Patent Application 2012-504552).
- RebA is evaluated as a sweetener having high sweetness and good sweetness and is widely used.
- Other Rebs are also found to have their own sweetness and associated taste.
- Rebaudioside M is considered to have good taste among steviol glycosides, but many can not be obtained from natural stevia plants, and its availability is considered to be a problem.
- the present invention provides a highly rebaudioside M-containing non-genetically modified stevia plant containing rebaudioside M at a high content as compared to a wild-type stevia species, and a method for producing and screening the plant.
- the present invention provides the following.
- [1-1] A highly rebaudioside M-containing non-genetically modified Stevia plant characterized in that it contains 2% or more of rebaudioside M based on the total amount of steviol glycosides contained in leaves.
- [1-2] The plant body according to [1-1], further comprising rebaudioside D in an amount of 9.5% or more based on the total amount of steviol glycosides contained in the leaves.
- the plant body according to [1-1] or [1-2] having at least one genetic feature of the following (1) to (5): (1) It is homozygous for an allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is T.
- [1-9] The plant according to any one of [1-1] to [1-4], and the seed, tissue, tissue culture or cell extract according to [1-5].
- [1-11] A process for obtaining an extract from a plant according to any one of [1-1] to [1-4], a seed, a tissue, a tissue culture or cells according to [1-5]
- a process for producing a rebaudioside M-containing extract, comprising [1-12] A method for producing rebaudioside M, comprising the step of purifying rebaudioside M from the rebaudioside M-containing extract according to [1-11].
- a food or drink comprising a step of mixing the extract obtained by the method described in [1-13] and / or rebaudioside M obtained by the method described in [1-12] and / or other components , A method of producing a sweetening composition, a fragrance or a medicine.
- a primer set comprising a forward primer having or including any continuous 15 base or more sequence in SEQ ID NO: 1 and a reverse primer having or any arbitrary 15 base or more sequence in SEQ ID NO: 2
- a primer set comprising a forward primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 3 and a reverse primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 4
- a primer set comprising a forward primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 5 and a reverse primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 6
- a primer set comprising a forward primer having or containing an arbitrary continuous 15 or more base sequence in SEQ ID NO: 7 and a reverse primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 8 5)
- a primer set comprising a forward primer having or including any continuous 15 base or more sequence in SEQ ID NO: 9 and a reverse primer having or including any continuous 15 base or more sequence in SEQ
- a kit comprising the primer set described in [1-17] and optionally a restriction enzyme,
- the primer set includes a forward primer having or including any continuous sequence of 15 or more bases in SEQ ID NO: 1
- it contains a restriction enzyme XbaI
- the primer set includes a forward primer having or including any continuous sequence of 15 or more bases in SEQ ID NO: 3
- it contains a restriction enzyme KpnI
- the primer set includes a forward primer having or including any continuous sequence of 15 or more bases in SEQ ID NO: 5
- it contains a restriction enzyme AflII When the primer set includes a forward primer having or including any continuous sequence of 15 or more bases in SEQ ID NO: 9, the restriction enzyme PvuI is included. Said kit.
- a probe comprising a base sequence shown in any one of SEQ ID NOs: 55 to 64, which may be bound to a detectable label.
- the probe according to [1-19] which has a fluorescent label, a dye or a binding moiety.
- [1-21] PCR amplification of the test plant's genomic DNA using the primer set described in [1-17] for the purpose of detecting at least one polymorphic marker selected from the group consisting of P01 to P05 And, if the polymorphic marker is at least one selected from the group consisting of P01 to P03 and P05, the PCR product obtained by the PCR amplification is treated with a restriction enzyme to obtain a restriction enzyme-treated product
- the restriction enzyme is at least one selected from the group consisting of XbaI, KpnI, AflII and PvuI.
- the polymorphic marker comprises P02 and P05.
- the restriction enzyme comprises KpnI and PvuI.
- the plant body obtained by the screening contains 2% or more of rebaudioside M based on the total amount of steviol glycosides contained in the leaves. Method described.
- the present invention also provides the following.
- [2-1] A highly rebaudioside M-containing non-genetically modified Stevia plant characterized in that it contains 2% or more of rebaudioside M based on the total amount of steviol glycosides contained in dried leaves.
- [2-2] The plant body according to the above [2-1], which further contains rebaudioside D at 9.5% or more based on the total amount of steviol glycosides contained in dried leaves.
- [2-3] The plant described in the above [2-1] or [2-2], which is positive for at least one polymorphic marker selected from the group consisting of P01, P02, P03, P04 and P05.
- [2-8] Total steviol contained in dried leaves, including the step of crossing the stevia plant according to any one of the above [2-1] to [2-3] with the second stevia plant A method for producing a high rebaudioside M-containing stevia plant, comprising 2% or more of rebaudioside M based on the amount of glycosides.
- [2-9] The method according to the above [2-8], wherein the second plant is a Stevia plant according to any one of the above [2-1] to [2-3].
- [2-10] The plant body according to any one of the above [2-1] to [2-3], the seed according to the above [2-4], or the dried leaf according to the above [2-5] Extract.
- [2-11] A food or drink, a sweetening composition, a flavor or a medicine comprising the extract according to the above [2-10].
- a primer set comprising a forward primer having or including any continuous 15 base or more sequence in SEQ ID NO: 1 and a reverse primer having or any arbitrary 15 base or more sequence in SEQ ID NO: 2
- a primer set comprising a forward primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 3 and a reverse primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 4
- a primer set comprising a forward primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 5 and a reverse primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 6
- a primer set comprising a forward primer having or containing an arbitrary continuous 15 or more base sequence in SEQ ID NO: 7 and a reverse primer having or containing any continuous 15 base or more sequence in SEQ ID NO: 8 5)
- a primer set comprising a forward primer having or including any continuous 15 base or more sequence in SEQ ID NO: 9 and a reverse primer having or including any continuous 15 base or more sequence in SEQ
- a kit comprising at least one primer set selected from (1) to (5) described in the above [2-17] and a restriction enzyme,
- the restriction enzyme is XbaI
- the restriction enzyme is KpnI
- the restriction enzyme is AflII
- the restriction enzyme is PvuI.
- a probe comprising a base sequence shown in any one of SEQ ID NOs: 1 to 10 which may be bound to a detectable label.
- the genomic DNA of the test plant is described above in [2-17].
- the restriction enzyme is at least one selected from the group consisting of XbaI, KpnI, AflII and PvuI.
- a Stevia plant body containing more rebaudioside M it is possible to obtain a Stevia plant body containing more rebaudioside M, a means for producing such a plant body, a leaf obtained from such a plant body, a food containing rebaudioside M obtained from this leaf or It will be possible to provide beverages.
- FIG. 1 shows an electropherogram obtained by marker detection of population I.
- FIG. 2 shows an electropherogram obtained by marker detection of population II.
- the present invention is characterized in that it contains rebaudioside M in an amount of 2% or more based on the total amount of steviol glycosides contained in leaves (for example, dried leaves or fresh leaves).
- a highly rebaudioside M-containing non-genetically modified Stevia plant (hereinafter, sometimes referred to as “plant of the present invention” or “stevia plant of the present invention”) is provided.
- the Stevia plant of the present invention is a species derived from a wild species Stevia plant, but is a gene whose mutation has occurred so that rebaudioside M is high. And, the mutation of the gene is generated non-genetically (described later).
- the high rebaudioside M-containing non-genetically modified Stevia plant comprises 2 to 4.6% rebaudioside M based on the total amount of steviol glycosides contained in leaves (eg, dried leaves or fresh leaves).
- Stevia plants characterized by being characterized as high rebaudioside M-containing non-genetically modified stevia plants and containing 4.7% or more of rebaudioside M are characterized as super high rebaudioside M-containing non-genes It may be called a recombinant stevia plant.
- Total Steviol Glycoside does not include unknown steviol glycosides, nor does it include steviol glycosides present below the detection limit.
- total steviol glycosides include rebaudioside A, rebaudioside B, rebaudioside M, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside I, rebaudioside J, rebaudioside K, rebaudioside N, rebaudioside O, rebaudioside O, rebaudioside Q.
- the total steviol glycoside comprises rebaudioside A, rebaudioside B, rebaudioside M, rebaudioside D, rebaudioside F, rebaudioside F, and steviol
- the total steviol glycoside is rebaudioside A , Rebaudioside M, Rebaudioside D, Rebaudioside F, Rebaudioside M, Rebaudioside N, Rebaudioside O, and Steviol.
- the rebaudioside M (RebM) content of containing 2% or more of rebaudioside M with respect to the total amount of steviol glycosides contained in the leaves is a steviol glycoside obtained from the leaves (eg, dried leaves or fresh leaves)
- the lower limit of the RebM / TSG value is 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, when expressed as RebM / TSG% as a ratio to the total amount %, 10% or more, 12% or more, 14% or more, 16% or more, 18% or more, 20% or more, 22% or more, 24% or more, 26% or more, 28% or more, 30% or more, 32% or more 34% or more, 36% or more, 38% or more.
- the upper limit of the RebM / TSG value is 15% or less, 16% or less, 18% or less, 20% or less, 22% or less, 24% or less, 26% or less, 28% or less, 30% or less, 32% or less 34% or less, 36% or less, 38% or less, and 40% or less.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but those having 2% or more and less than 4.7% have high rebaudioside M-containing phenotype, 4.7% or more and 15 % Or less may be referred to as the ultra-high rebaudioside M-containing phenotype.
- the plant body of the present invention may contain 0.19 g or more of rebaudioside M in 100 g of dried leaves.
- rebaudioside M is 0.19 g or more, 0.20 g or more, 0.25 g or more, 0.30 g or more, 0.35 g or more, per 100 g of the dried leaves.
- the dry leaf of the plant of the present invention refers to a plant in which the water content is reduced to 3 to 4% by weight by drying the fresh leaf of the stevia plant of the present invention.
- the plant body of the present invention is 1.00 g or more, 1.05 g or more, 1.10 g or more, 1.15 g or more, 1.20 g or more, 1.25 g or more, 1.30 g or more in 100 g of dried leaves.
- the combination of the contents of rebaudioside M and D is not particularly limited and is optional.
- the plant body of the present invention contains 1.03 g or more of rebaudioside M and 1.1 g or more of rebaudioside D in 100 g of dried leaves.
- leaves of the plant of the present invention are treated with wild-type stevia when the amount (g) of rebaudioside M contained in 100 g of leaves of the wild-type stevia plant is 100%.
- the content may be higher than or equal to 2800% or more, 2900% or more, or 3000% or more.
- the Stevia plant of the present invention is also applicable to RebM / RebD when the content of rebaudioside M (RebM) and rebaudioside D (RebD) in leaves (for example, dried leaves or fresh leaves) is represented by the ratio RebM / RebD.
- the lower limit of the value is 0.2 or more, 0.3 or more, 0.4 or more, 0.5 or more, 0.6 or more, 0.8 or more, 1.0 or more.
- the upper limit of the value of RebM / RebD is 0.3 or less, 0.4 or less, 0.5 or less, 0.6 or less, 0.8 or less, 1.0 or less, 1.1 or less, 1.2 or less It is characterized by being.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but is preferably 0.2 or more and 1.2 or less, or 0.6 or more and 1.1 or less.
- the Stevia plant of the present invention has a content of rebaudioside M (RebM) and rebaudioside D (RebD) in leaves (for example, dried leaves or fresh leaves) as a ratio to the total amount of steviol glycosides (RebD + RebM) / TSG%
- the lower limit of the value of (RebD + RebM) / TSG is 14% or more, 16% or more, 18% or more, 20% or more, 22% or more, 24% or more, 26% or more, 28% or more, 30% or more 32% or more, 34% or more, 36% or more, and 38% or more.
- the upper limit of the value of (RebD + RebM) / TSG is 18% or less, 20% or less, 22% or less, 24% or less, 26% or less, 28% or less, 30% or less, 32% or less, 34% or less, 36% % Or less, 38% or less, or 40% or less.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but is preferably 14% or more and 40% or less, or 16% or more and 40% or less.
- the plant of the present invention may have a total amount of steviol glycosides less than that of the wild type.
- the total amount of steviol glycosides less than 19 g may be included in 100 g of dried leaves. That is, when dried leaves are obtained from the plant body of the present invention, the total amount of steviol glycosides per 100 g of the dried leaves is less than 19 g, less than 18 g, less than 17 g, less than 16 g, less than 15 g, less than 14 g, less than 13 g, less than 12 g Mean less than 11 g, less than 10 g, less than 9 g, less than 8 g, less than 7 g.
- the Stevia plant of the present invention is a RebM / RebA when the content of rebaudioside M (RebM) and rebaudioside A (RebA) in 100 g of leaves (for example, dried leaves or fresh leaves) is represented by the ratio of RebM / RebA.
- the lower limit of the value of is 0.03 or more, 0.04 or more, 0.05 or more, 0.06 or more, 0.08 or more, 0.10 or more, 0.12 or more, or 0.14 or more.
- the upper limit of the value of RebM / RebA is 0.08 or less, 0.10 or less, 0.12 or less, 0.14 or less, 0.16 or less, 0.18 or less, 0.18 or less, 0.20 or less, 0.24 or less , 0.26 or less.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but is preferably 0.03 or more and 0.26 or less, or 0.10 or more and 0.26 or less.
- the lower limit of the value of (RebA + RebM) / TSG is 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 12% or more, 14% or more , 16% or more, 18% or more, 20% or more, 22% or more, 24% or more, 26% or more, 28% or more, 30% or more, 32% or more, 34% or more, 36% or more, 38% or more It is characterized by On the other hand, the upper limit of the value of (RebA + RebM) / TSG is 10% or less, 12% or less, 14% or less, 16% or less, 18% or less,
- the Stevia plant of the present invention is a mutant in which rebaudioside M is raised.
- This mutation has at least one genetic feature of the following (1) to (5) (hereinafter sometimes referred to as "the genetic feature of the present invention”).
- (1) It is homozygous for an allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is T.
- (2) It is homozygous for an allele in which the base at a position corresponding to position 40 of SEQ ID NO: 37 is T.
- the portion corresponding to positions 55 to 72 of SEQ ID NO: 42 is homozygous for the deleted allele.
- (5) It is homozygous for an allele in which the base at the position corresponding to position 50 of SEQ ID NO: 43 is A.
- the “position (or part) corresponding to” means in the genome if a sequence identical to the reference sequence (eg, SEQ ID NO: 35, 37, 39, 42, 43 etc.) is present in the genome Indicates a position or part in the sequence (for example, positions 44, 40, 41, 55 to 72, 50, etc.), and if there is no sequence identical to the reference sequence in the genome, It means the position or part corresponding to the position or part in the reference sequence in the sequence corresponding to the reference sequence.
- a sequence identical to the reference sequence eg, SEQ ID NO: 35, 37, 39, 42, 43 etc.
- the genomic DNA of the target Stevia plant is amplified with a primer that can amplify the reference sequence by PCR, and sequencing of the amplification product is It can be determined by performing alignment analysis of the obtained sequence and the reference sequence.
- Non-limiting examples of the sequence corresponding to the reference sequence include, for example, 60% or more, 70% or more, 75% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more of the reference sequence , 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97 %, 98% or more, 98.1% or more, 98.4% or more, 98.7% or more, 99% or more, 99.2% or more, 99.5% or more, 99.5% or more or 99.8% or more of sequence identity
- the base sequence which has is mentioned.
- the position or part corresponding to the position or part in the reference sequence in the sequence corresponding to the reference sequence in the genome can be determined in consideration of the base sequence before and after the position or part in the reference sequence. For example, alignment analysis between a reference sequence and a sequence corresponding to a reference sequence in the genome may be performed to determine a position or a portion corresponding to a position or a portion in the reference sequence in the sequence corresponding to the reference sequence in the genome. it can.
- the genome of the Stevia plant has a portion consisting of the same base sequence as SEQ ID NO: 35
- a position corresponding to position 44 of SEQ ID NO: 35 is a position 44 from the 5 'side of a portion consisting of the same base sequence as SEQ ID NO: 35 in the genome.
- the genome of the Stevia plant has a portion which is not identical to SEQ ID NO: 35 but has a base sequence corresponding thereto, the genome does not have a portion consisting of a base sequence identical to SEQ ID NO: 35, “The position corresponding to position 44 of SEQ ID NO: 35” does not necessarily correspond to position 44 from the 5 ′ side of the portion corresponding to SEQ ID NO. 35, but the base sequence etc. before and after position 44 of SEQ ID NO. In consideration of this, it is possible to identify "the position corresponding to position 44 of SEQ ID NO: 35" in the genome of such a Stevia plant.
- the position corresponding to position 44 of SEQ ID NO: 35 is specified in the genome of Stevia plant can do.
- the portion consisting of the nucleotide sequence corresponding to SEQ ID NO: 35 is, for example, 60% or more, 70% or more, 75% or more, 80% or more, 81% or more, 82% or more, 82% or more of the nucleotide sequence of SEQ ID NO: 35 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more 96% or more, 97% or more, 98% or more, 98.1% or more, 98.4% or more, 98.7% or more, 99% or more, 99.2% or more, 99.5% or more, or 99. It means a portion consisting of a nucleotide sequence having 8% or more of sequence identity.
- a portion consisting of a nucleotide sequence corresponding to SEQ ID NO: 35 is a forward primer that hybridizes to a complementary sequence of a portion 15-25 bases long from the 5 'end of SEQ ID NO: 35; Included are portions of the genome of Stevia plants that can be amplified by PCR using a reverse primer that hybridizes to a portion of 15-25 bases in length from the 3 'end side of 35.
- the genetic feature (1) is described as an example for the sake of simplicity, but the same is true for the genetic features (2) to (5).
- a portion consisting of a nucleotide sequence corresponding to SEQ ID NO: 35 is a PCR using, for example, a forward primer containing the nucleotide sequence of SEQ ID NO: 45 and a reverse primer containing the nucleotide sequence of SEQ ID NO: 46
- a portion consisting of a nucleotide sequence corresponding to SEQ ID NO: 39 is a PCR using, for example, a forward primer containing the nucleotide sequence of SEQ ID NO: 49 and
- the "allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is T” comprises the base sequence of SEQ ID NO: 55, 65 or 75.
- the “allele in which the base at a position corresponding to position 40 of SEQ ID NO: 37 is T” comprises the base sequence of SEQ ID NO: 57, 67 or 77.
- the “allele in which the base at the position corresponding to position 41 of SEQ ID NO: 39 is C” comprises the base sequence of SEQ ID NO: 59, 69 or 79.
- the “allele in which the part corresponding to positions 55 to 72 of SEQ ID NO: 42 is deleted” comprises the base sequence of SEQ ID NO: 61, 71 or 81.
- the “allele in which the base at the position corresponding to position 50 of SEQ ID NO: 43 is A” comprises the base sequence of SEQ ID NO: 63, 73 or 83.
- the position selected from the group consisting of a portion corresponding to positions 55 to 72 of 42 and (5) a position corresponding to position 50 of SEQ ID NO: 43 is “polymorphic site of the present invention” or “mutant site of the present invention It may be called ".”
- a mutation selected from the group consisting of a mutation from A to A may be referred to as
- the above genetic features include PCR method, TaqMan PCR method, sequencing method, microarray method, invader method, TILLING method, RAD (random amplified polymorphic DNA) method, restriction fragment length polymorphism (RFLP) method, PCR-SSCP method , AFLP (amplified fragment length polymorphism) method, SSLP (simple sequence length polymorphism) method, CAPS (cleaved amplified polymorphic sequence) method, dCAPS (derived cleaved amplified polymorphic sequence) method, allele specific oligonucleotide (ASO) method, ARMS method , Denaturing agent gradient gel electrophoresis (DGGE) method, CCM (chemical cleavage of mismatch) method, DOL method, MALDI-TOF / MS method, TDI method, padlock probe method, molecular beacon method, DASH (dynamic allele specific hybridization) Law, UCAN method, ECA method, PINPOI NT method, PROBE (
- the genetic features described above can be detected as "polymorphic marker positive” using polymorphic markers developed by the present inventors.
- the polymorphic marker is at least one selected from the group consisting of P01 to P05.
- “Positive for P01” refers to PCR amplification of genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 1 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 2 It means that the product (about 383 bp in length: eg, SEQ ID NO: 21 or 22) is treated with XbaI restriction enzyme to obtain only a band of about 383 bp in length (eg, SEQ ID NO: 21).
- a restriction enzyme-treated product eg, SEQ ID NO: 23
- the candidate plant becomes P01 negative.
- “Positive for P02” refers to PCR amplification of genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 3 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 4 This means that the product (297 bp in length) (for example, SEQ ID NO: 24 or 25) can be treated with KpnI restriction enzyme to obtain only a band of about 297 bp in length (for example, SEQ ID NO: 24).
- the candidate plant is P02 negative if it results in an approximately 258 bp restriction product (eg, SEQ ID NO: 26).
- “Positive for P03” means that PCR amplification is performed on genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 5 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 6 This means that the product (about 390 bp in length) (for example, SEQ ID NO: 27 or 28) can be treated with AflII restriction enzyme to obtain only a band of about 390 bp in length (for example, SEQ ID NO: 27).
- the candidate plant is P03 negative if it produces a restriction product of approximately 347 bp (eg, SEQ ID NO: 29).
- Positive for P04 is about 140 bp when PCR amplification is performed on the genomic DNA of the candidate plant using the forward primer having the nucleotide sequence shown in SEQ ID NO: 7 and the reverse primer having the nucleotide sequence shown in SEQ ID NO: 8 It means that it produces only the PCR product of SEQ ID NO: 30 (for example, SEQ ID NO: 30) and is negative if it produces PCR products of 140 bp (for example, SEQ ID NO: 30) and 158 bp (for example, SEQ ID NO: 34).
- “Positive for P05” refers to PCR amplification of genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 9 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 10
- the product (about 288 bp in length) (for example, SEQ ID NO: 31 or 32) can be treated with PvuI restriction enzyme to obtain only a band of about 288 bp in length (for example, SEQ ID NO: 31).
- the candidate plant is P05 negative if it produces a restriction enzyme treated product (eg, SEQ ID NO: 33) of about 240 bp.
- “about” means ⁇ 5 bp.
- the restriction enzyme treatment can be carried out according to the conditions recommended by the vendor of each restriction enzyme used.
- the item “3. Method of screening a plant of the present invention” described later can be referred to. It has been confirmed in the Examples that the genetic features (eg, polymorphisms of the polymorphism marker positive polymorphisms) have a statistical correlation with phenotypes of high rebaudioside M content and / or high rebaudioside D content. .
- Rebaudiosides M and D are extracted in the form of an extract by reacting fresh leaves or dried leaves of the plant of the present invention with an appropriate solvent (an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone).
- an appropriate solvent an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone.
- Extraction conditions etc. can refer to the method described in Ohta et al., J. Appl. Glycosci., Vol. 57, No. 3 (2010) or WO 2010/038911 and the methods described in the following examples. .
- ethyl acetate and other organic solvents gradient of water, high performance liquid chromatography (HPLC), gas chromatography, time-of-flight mass spectrometry (Time- Rebaudioside M can be purified by using known methods such as of-Flight mass spectrometry (TOF-MS), ultra high performance liquid chromatography (UPLC) and the like.
- the rebaudioside M content according to the present invention can be determined according to the method described in Ohta et al., J. Appl. Glycosci., Vol. 57, No. 3 (2010) or WO 2010/038911 or the method described in the examples below. It can be measured. Specifically, fresh leaves can be sampled from the Stevia plants of the present invention, and measurement can be performed by performing LC / MS-MS.
- the plant of the present invention includes not only whole plant but also plant organs (eg leaves, petals, stems, roots, seeds etc.), plant tissues (eg epidermis, phloem, soft tissue, xylem, vascular bundle, fence) Tissue, cancellous tissue, etc.) or various forms of plant cells (eg, suspension culture cells), protoplasts, leaf sections, callus, etc. may be included. Also, the leaves may be the dry leaves mentioned above.
- the plants of the present invention may also include tissue cultures or cultured plant cells. By culturing such tissue cultures or plant culture cells, plants can be regenerated. Examples of tissue cultures or plant cultured cells of plants of the present invention include embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections and callus, etc. It is not limited.
- the present invention relates to a leaf (eg, dried leaf or fresh leaf) comprising a step of crossing the Stevia plant of the present invention with a second Stevia plant.
- a method for producing a high rebaudioside M-containing stevia plant comprising 2% or more of rebaudioside M based on the total amount of steviol glycosides contained (hereinafter sometimes referred to as "the production method of the present invention") I will provide a.
- the "high rebaudioside M-containing Stevia plant characterized in that it contains 2% or more rebaudioside M with respect to the total amount of steviol glycosides contained in the leaves" produced by the method has the same expression as the plant of the present invention It has type and genetic character.
- rebaudioside M when leaves (eg, dried leaves or fresh leaves) are obtained from a plant obtained by the production method of the present invention, rebaudioside M at 2% or more relative to the total amount of steviol glycosides contained in the leaves including.
- the lower limit of the value of RebM / TSG is 2% or more, 3% or more, when the content of rebaudioside M (RebM) is expressed as RebM / TSG% as a ratio to the total amount of steviol glycosides obtained from leaves.
- the upper limit of the RebM / TSG value is 15% or less, 16% or less, 18% or less, 20% or less, 22% or less, 24% or less, 26% or less, 28% or less, 30% or less, 32% or less 34% or less, 36% or less, 38% or less, or 40% or less.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but is preferably 2% or more and 20% or less, or 7% or more and 15% or less.
- the plant body obtained by the production method of this invention may contain 0.19 g or more of rebaudioside M in 100 g of dried leaves.
- rebaudioside M is 0.19 g or more, 0.20 g or more, 0.25 g or more, 0.30 g or more, 0.35 g or more, per 100 g of the dried leaves.
- the plant body obtained by the production method of the present invention is 1.00 g or more, 1.05 g or more, 1.10 g or more, 1.15 g or more, 1.20 g or more, 1.25 g or more in 100 g of dried leaves.
- the combination of the contents of rebaudioside M and D is not particularly limited and is optional.
- the plant body obtained by the production method of the present invention contains 1.03 g or more of rebaudioside M and 1.1 g or more of rebaudioside D in 100 g of dried leaves.
- the leaf of the plant obtained by the production method of the present invention is 100% of the amount (g) of rebaudioside M contained per 100 g of leaf of a wild-type stevia plant (for example, dried leaf or fresh leaf).
- rebaudioside M is 300% or more, 400% or more, 500% or more, 600% or more, 700% or more, 800% or more, 900% or more, 900% or more, 1100% or more, 1200% or more, 1300% or more as compared with wild type Stevia species Or more, 1400% or more, 1500% or more, 1600% or more, 1700% or more, 1800% or more, 12000% or more, 2000% or more, 2100% or more, 2200% or more, 2300% or more, 2400% or more, 2500% or more, 2600% or more, 2700% or more, 2800% or more, 2900% or more, 3000% or more higher content may be included
- the plant body obtained by the production method of the present invention is the case where the content of rebaudioside M (RebM) and rebaudioside D (RebD) in leaves (for example, dried leaves or fresh leaves) is represented by the ratio of RebM / RebD.
- the lower limit value of RebM / RebD is 0.2 or more, 0.3 or more, 0.4 or more, 0.5 or more, 0.6 or more, 0.8 or more, 1.0 or more.
- the upper limit of the value of RebM / RebD is 0.3 or less, 0.4 or less, 0.5 or less, 0.6 or less, 0.8 or less, 1.0 or less, 1.1 or less, 1.2 or less It is characterized by being.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but is preferably 0.2 or more and 1.2 or less, or 0.6 or more and 1.1 or less.
- the plant body obtained by the production method of the present invention is characterized in that the content of rebaudioside M (RebM) and rebaudioside D (RebD) in leaves (for example, dried leaves or fresh leaves) is a ratio to the total steviol glycoside ( When expressed as RebD + RebM) / TSG%, the lower limit of the (RebD + RebM) / TSG value is 14% or more, 16% or more, 18% or more, 20% or more, 22% or more, 24% or more, 26% or more, 28% Above, 30% or more, 32% or more, 34% or more, 36% or more, 38% or more.
- the upper limit of the value of (RebD + RebM) / TSG is 18% or less, 20% or less, 22% or less, 24% or less, 26% or less, 28% or less, 30% or less, 32% or less, 34% or less, 36% % Or less, 38% or less, or 40% or less.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but is preferably 14% or more and 40% or less, or 16% or more and 40% or less.
- the plant obtained by the production method of the present invention may have a total amount of steviol glycosides smaller than that of the wild type.
- the total amount of steviol glycosides less than 19 g may be included in 100 g of dried leaves. That is, when dried leaves are obtained from the plant body of the present invention, the total amount of steviol glycosides per 100 g of the dried leaves is less than 19 g, less than 18 g, less than 17 g, less than 16 g, less than 15 g, less than 14 g, less than 13 g, less than 12 g Mean less than 11 g, less than 10 g, less than 9 g, less than 8 g, less than 7 g.
- the plant body obtained by the production method of the present invention has the content of rebaudioside M (RebM) and rebaudioside A (RebA) in 100 g of leaves (for example, dried leaves or fresh leaves) as a ratio to the total amount of steviol glycosides.
- RebM rebaudioside M
- RebA rebaudioside A
- the lower limit of the value of (RebA + RebM) / TSG is 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 12% 14% or more, 16% or more, 18% or more, 20% or more, 22% or more, 26% or more, 28% or more, 30% or more, 32% or more, 34% or more, 36% or more 38% or more and 40% or more.
- the upper limit of the value of (RebA + RebM) / TSG is 30% or less, 32% or less, 34% or less, 36% or less, 38% or less, 40% or less, 42% or less, 44% or less, 46% or less, 48% or less % Or less, 50% or less, 52% or less, 54% or less, 56% or less, 58% or less, 60% or less, 62% or less, 64% or less, 66% or less, 68% or less, 70% or less, 72% or less 74% or less, 76% or less, 78% or less, and 80% or less.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit is a combination exceeding the lower limit, but is preferably 4% to 80%, or 40% to 80%.
- the plant body obtained by the production method of the present invention has at least one genetic feature of the following (1) to (5) in which rebaudioside M becomes high.
- (1) It is homozygous for an allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is T.
- (2) It is homozygous for an allele in which the base at a position corresponding to position 40 of SEQ ID NO: 37 is T.
- (3) It is homozygous for an allele in which the base at the position corresponding to position 41 of SEQ ID NO: 39 is C.
- the portion corresponding to positions 55 to 72 of SEQ ID NO: 42 is homozygous for the deleted allele.
- polymorphic marker positive is at least one selected from the group consisting of P01 to P05.
- “Positive for P01” refers to PCR amplification of genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 1 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 2 It means that the product (about 383 bp in length: eg, SEQ ID NO: 21 or 22) is treated with XbaI restriction enzyme to obtain only a band of about 383 bp in length (eg, SEQ ID NO: 21).
- a restriction enzyme-treated product eg, SEQ ID NO: 23
- the candidate plant becomes P01 negative.
- “Positive for P02” refers to PCR amplification of genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 3 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 4 This means that the product (297 bp in length) (for example, SEQ ID NO: 24 or 25) can be treated with KpnI restriction enzyme to obtain only a band of about 297 bp in length (for example, SEQ ID NO: 24).
- the candidate plant is P02 negative if it results in an approximately 258 bp restriction product (eg, SEQ ID NO: 26).
- “Positive for P03” means that PCR amplification is performed on genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 5 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 6 This means that the product (about 390 bp in length) (for example, SEQ ID NO: 27 or 28) can be treated with AflII restriction enzyme to obtain only a band of about 390 bp in length (for example, SEQ ID NO: 27).
- the candidate plant is P03 negative if it produces a restriction product of approximately 347 bp (eg, SEQ ID NO: 29).
- Positive for P04 is about 140 bp when PCR amplification is performed on the genomic DNA of the candidate plant using the forward primer having the nucleotide sequence shown in SEQ ID NO: 7 and the reverse primer having the nucleotide sequence shown in SEQ ID NO: 8 It means that it produces only the PCR product of SEQ ID NO: 30 (for example, SEQ ID NO: 30) and is negative if it produces PCR products of 140 bp (for example, SEQ ID NO: 30) and 158 bp (for example, SEQ ID NO: 34).
- “Positive for P05” refers to PCR amplification of genomic DNA of a candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 9 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 10
- the product (about 288 bp in length) (for example, SEQ ID NO: 31 or 32) can be treated with PvuI restriction enzyme to obtain only a band of about 288 bp in length (for example, SEQ ID NO: 31).
- the candidate plant is P05 negative if it produces a restriction enzyme treated product (eg, SEQ ID NO: 33) of about 240 bp.
- “about” means ⁇ 5 bp.
- the restriction enzyme treatment can be carried out according to the conditions recommended by the vendor of each restriction enzyme used.
- crossing means that the plant of the present invention (first generation (S1)) and the second plant (S1) are crossed with each other to produce their plantlets (the present invention) Means to obtain a plant (second generation (S2))) produced by the production method of As a crossing method, back crossing is preferable.
- the “backcross” means a plantlet (S2) produced between a plant of the present invention and a second plant, and a plant of the present invention (that is, a plant having a genetic feature of the present invention) (S1) A method of producing a plant having genetic features of the present invention by crossing it with (S1).
- the second plant (S1) used in the production method of the present invention has the same phenotype and genetic property as the plant of the present invention, it is substantially backcrossed.
- the gene polymorphism of the present invention is inherited according to Mendel's law, and accordingly, the phenotype correlated with the gene polymorphism, that is, the phenotype of high rebaudioside M content is also inherited according to Mendel's law.
- the plants of the present invention can be produced by self-fermentation. Selfing can be carried out by causing the pollen of the stamen of the plant of the present invention to self-pollinate the stamen of the plant of the present invention.
- the plants produced by the production method of the present invention have the same phenotypic and genetic properties as the plants of the present invention
- the plants produced by the production method of the present invention are further subjected to a third stevia plant
- a third stevia plant By producing a high rebaudioside M-containing stevia plant characterized by containing 2% or more of rebaudioside M based on the total amount of steviol glycosides contained in the leaves (eg, dried leaves or fresh leaves). It is also possible.
- the plant of the present invention can be produced by regenerating a plant by culturing the above-described tissue culture or plant culture cell.
- the culture conditions are the same as those for culturing tissue cultures or plant culture cells of wild-type Stevia plants, and are known (Protocols for in vitro cultures and secondary metabolic analysis of aromatic and medicinal plants, Method in molecular biology, vo. 1391, pp 113-123.).
- the plant of the present invention can also be prepared by incorporating the above polymorphism into a wild-type stevia plant by non-genetically modified techniques.
- non-genetic recombination technique include methods for inducing mutations in genes of host cells (or host plants) without introducing foreign genes. Such methods include methods in which plant cell mutagens are allowed to act. Such mutagens include ethyl methane sulfonic acid (EMS) and sodium azide and the like.
- EMS ethyl methane sulfonic acid
- EMS ethyl methane sulfonic acid
- the treatment time is 1 to 48 hours, 2 to 36 hours, 3 to 30 hours, 4 to 28 hours, 5 to 26 hours, and 6 to 24 hours.
- the procedure of treatment itself is known, it can be carried out by immersing the water-absorbent seed that has undergone the water absorption process in the treatment solution containing the mutagen at the above concentration for the treatment time.
- a method of irradiating plant cells with radiation such as X-rays, ⁇ -rays or ultraviolet rays or light
- radiation such as X-rays, ⁇ -rays or ultraviolet rays or light
- a suitable ultraviolet radiation dose ultraviolet lamp intensity, distance, time
- cells, calli and plants having a desired trait can be selected.
- the irradiation intensity at that time is 0.01 to 100 Gr, 0.03 to 75 Gr, 0.05 to 50 Gr, 0.07 to 25 Gr, 0.09 to 20 Gr, 0.1 to 15 Gr, 0.1 to 10 Gr, 0.1.
- the irradiation distance is 1 cm to 200 m, 5 cm to 100 m, 7 cm to 75 m, 9 cm to 50 m, 10 cm to 30 m, 10 cm to 20 m, 10 cm to 10 m, and the irradiation time is 1 minute to 2 Year, 2 minutes to 1 year, 3 minutes to 0.5 years, 4 minutes to 1 month, 5 minutes to 2 weeks, 10 minutes to 1 week.
- the intensity, distance and time of irradiation vary depending on the type of radiation and the condition to be irradiated (cell, callus, plant), but can be appropriately adjusted by those skilled in the art.
- plant cells are preferably returned to individual plants for more stable trait maintenance, as they may be mutated during culture.
- the plant of the present invention is a non-genetically modified Stevia plant, but a plant obtained by performing genetic recombination (for example, by genome editing) with the plant of the present invention as a host (for example, Plants that have been genetically modified using the plants of the invention as hosts and further added with other traits are not excluded from the scope of the present invention.
- the plant of the present invention and a plant having the same phenotype and genetic property as the plant of the present invention can be obtained by detecting the genetic feature of the present invention from the tissue of the plant. It can be screened.
- screening means identifying the plant of the present invention and the other plants and selecting the plant of the present invention. Therefore, the present invention provides, as another embodiment, high rebaudioside M-containing, which comprises the step of detecting the presence and / or absence of at least one of the following genetic features (1) to (5) from the genome of a test plant:
- the present invention provides a method of screening a type Stevia plant (hereinafter sometimes referred to as "the screening method of the present invention").
- the screening method of the present invention may further include the step of selecting from the test plants a plant in which the presence of at least one of the above-mentioned (1) to (5) genetic features is detected.
- the presence of the genetic features of the invention is (A) an allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is T, (B) an allele in which the base at a position corresponding to position 40 of SEQ ID NO: 37 is T, (C) an allele in which the base at a position corresponding to position 41 of SEQ ID NO: 39 is C, (D) an allele which is deleted from a portion corresponding to positions 55 to 72 of SEQ ID NO: 42, and (E) an allele whose base at a position corresponding to position 50 of SEQ ID NO: 43 is A Detection of the presence of the allele and / or (A) an allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is A, (B) an allele in which the base at a position corresponding to position 40 of SEQ ID NO: 37 is C, (C) an allele in which the base at a position corresponding to position 41 of SEQ ID NO: 39 is G
- the absence of the genetic features of the invention is (A) an allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is T, (B) an allele in which the base at a position corresponding to position 40 of SEQ ID NO: 37 is T, (C) an allele in which the base at a position corresponding to position 41 of SEQ ID NO: 39 is C, (D) an allele which is deleted from a portion corresponding to positions 55 to 72 of SEQ ID NO: 42, and (E) an allele whose base at a position corresponding to position 50 of SEQ ID NO: 43 is A Detection of the absence of the allele and / or (A) an allele in which the base at a position corresponding to position 44 of SEQ ID NO: 35 is A, (B) an allele in which the base at a position corresponding to position 40 of SEQ ID NO: 37 is C, (C) an allele in which the base at a position corresponding to position 41 of SEQ ID NO: 39 is G
- Specific examples of the method of detecting genetic features of the present invention include PCR, TaqMan PCR, sequencing, microarray, invader, TILLING, RAD, RFLP, PCR-SSCP, AFLP, SSLP , CAPS method, dCAPS method, ASO method, ARMS method, DGGE method, CCM method, DOL method, MALDI-TOF / MS method, TDI method, padlock probe method, molecular beacon method, DASH method, UCAN method, ECA method, PINPOINT Method, PROBE method, VSET method, Survivor assay, Sniper assay, Luminex assay, GOOD method, LCx method, SNaPshot method, Mass ARRAY method, pyrosequencing method, SNP-IT method, melting curve analysis method etc. It is not limited to
- a primer such that the 3 'terminal portion has a sequence complementary to the polymorphic site of the present invention.
- primers designed in this way are used, if the sample serving as the template has a polymorphism, the primer is fully hybridized to the template, so the polymerase extension reaction proceeds, but the template has the mutation of the present invention. If not, the extension reaction does not occur because the nucleotide at the 3 'end of the primer causes a mismatch with the template.
- PCR amplification is performed using such a primer, and the amplification product is analyzed by agarose gel electrophoresis etc., and if the amplification product of a predetermined size can be confirmed, the template which is the sample has a mutation. If no amplification product is present, it can be determined that the template has no mutation.
- the primer sequence is designed so that the polymorphism of the present invention and the primer sequence do not overlap, and that the gene mutation of the present invention can be PCR amplified, and the base sequence of the amplified nucleotide fragment is sequenced.
- the genetic features of the present invention can be detected.
- PCR and agarose gel electrophoresis see: Sambrook, Fritsch and Maniatis, "Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press.
- the TaqMan PCR method is a method using fluorescence-labeled allele-specific oligo and a PCR reaction with Taq DNA polymerase (Livak, KJ Genet. Anal. 14, 143 (1999); Morris T. et al., J. Clin. Microbiol. 34, 2933 (1996)).
- the sequencing method is a method of analyzing the presence or absence of a mutation by amplifying the region containing the mutation by PCR and sequencing the DNA sequence using Dye Terminator or the like (Sambrook, Fritsch and Maniatis, "Molecular Cloning: A Laboratory Manual "2nd Edition (1989), Cold Spring Harbor Laboratory Press).
- the DNA microarray is one in which one end of a nucleotide probe is immobilized on a support in the form of an array, and includes a DNA chip, a Gene chip, a microchip, a bead array and the like.
- a probe containing a sequence complementary to the polymorphism of the present invention By using a probe containing a sequence complementary to the polymorphism of the present invention, the presence or absence of the polymorphism of the present invention can be detected exhaustively.
- DNA microarray assays such as DNA chips include GeneChip assays (see Affymetrix; US Pat. Nos. 6,045,996, 5,925,525, and 5,858,659). GeneChip technology utilizes miniaturized high-density microarrays of oligonucleotide probes affixed to the chip.
- the invader method is a special method that recognizes two types of reporter probes specific to each allele of polymorphisms such as SNPs and hybridization of one type of invader probe to template DNA, and recognizes and cuts the structure of DNA. It is a combined method of cleaving DNA by the Cleavase enzyme having endonuclease activity (Livak, KJ Biomol. Eng. 14, 143-149 (1999); Morris T. et al., J. Clin. Microbiol. 34, 2933 (1996); Lyamichev, V. et al., Science, 260, 778-783 (1993), etc.).
- the TILLING (Targeting Induced Local Lesions in Genomes) method is a method for screening mutation mismatches in the genome of a mutagenized mutant population by PCR amplification and CEL I nuclease treatment.
- the screening method of the present invention may include the step of detecting the polymorphism marker positive of the present invention from the genome of the test plant.
- the process includes an operation of extracting genomic DNA from a test plant and detecting the polymorphic marker of the present invention on the genomic DNA.
- the polymorphic marker is at least one selected from the group consisting of P01 to P05.
- polymorphism marker positive means that it is positive for at least one marker selected from the group consisting of P01 to P05.
- the positive detection method of P01 to P05 is as described above.
- the screening method of the present invention may further include the step of selecting from the test plants the plants in which the polymorphism marker positive of the present invention has been detected.
- a method for screening high rebaudioside M-containing non-genetically modified Stevia plants comprising (1) A primer set comprising a forward primer containing the base sequence shown in SEQ ID NO: 1 and a reverse primer containing the base sequence shown in SEQ ID NO: 2, (2) A primer set comprising a forward primer containing the base sequence shown in SEQ ID NO: 3 and a reverse primer containing the base sequence shown in SEQ ID NO: 4, (3) A primer set comprising a forward primer containing the base sequence shown in SEQ ID NO: 5 and a reverse primer containing the base sequence shown in SEQ ID NO: 6, (4) a primer set comprising a forward primer containing the nucleotide sequence shown in SEQ ID NO: 7 and a reverse primer containing the nucle
- the primer set is not limited to one having the sequence of SEQ ID NO: 1 to 10.
- a forward primer up to 15 bases upstream from the 3 'end of SEQ ID NO: 1, 3, 5, 7 or 9
- a reverse primer may be a sequence (see the table below) up to 15 bases upstream from the 3' end of SEQ ID NO: 2, 4, 6, 8 or 10 What is necessary is to have at the 3 'end.
- Such primers may be 15 to 50 bases long and 20 to 45 bases long.
- the primer set is not limited to one having the sequence of SEQ ID NO: 1 to 10.
- a forward primer it has any continuous sequence of 15 or more bases in SEQ ID NO: 1, 3, 5, 7 or 9 or Any reverse primer may be used as long as it has or contains any continuous sequence of 15 or more bases in SEQ ID NO: 2, 4, 6, 8 or 10.
- Or ′ ′) a primer set comprising a forward primer having or including any continuous 15 base or more sequence
- the screening method of the present invention may further include the step of measuring the RebM content of a tissue (eg, a leaf) of a test Stevia plant in which the genetic characteristics of the present invention have been detected.
- the measurement of RebM content is as described in the section of the plant of the present invention.
- an individual having a high RebM content is selected from the test Stevia plants in which the genetic features of the present invention have been detected, and this is crossed with another Stevia plant to obtain offspring obtained.
- the screening method of the present invention may be applied to plants. Therefore, the screening method of the present invention may include one or more of the following steps.
- An individual having a high RebM content to be selected is, for example, up to the top 50%, the top 40%, and the top 30 in the height of the RebM content among the tested Stevia plants in which the genetic characteristics of the present invention are detected. %, Up to top 20%, top 10%, top 5%, top 4%, top 3%, top 2% or top 1% individuals etc. Also, other Stevia plants to be crossed may or may not contain the genetic features of the present invention. In the above embodiment, steps (iv) to (vii) can be repeated multiple times. In this way, Stevia plants with higher RebM content can be screened.
- the test Stevia plant may be a natural plant or a non-genetically modified plant.
- the non-genetically modified plants are as described in the plant section of the present invention.
- the test stevia plant may include a mutagenized stevia plant and its progeny plants.
- the mutagenesis treatment is as described in the section of the plant of the present invention, and includes treatment with a mutagenizing agent, treatment with irradiation of radiation or light, and the like.
- the present invention provides the primer set described above, for example, the group consisting of (1) to (5), (1 ′) to (5 ′) and (1 ′ ′) to (5 ′ ′) above.
- the present invention further provides a primer set capable of amplifying, by PCR, a region having a base sequence selected from the group consisting of SEQ ID NOs: 35 to 44, for example, a forward primer comprising the base sequence of SEQ ID NO: 45;
- the present invention provides a probe (hereinafter sometimes referred to as "the probe of the present invention") capable of detecting the presence and / or absence of the genetic feature of the present invention.
- the probes of the invention may have structures suitable for various detection methods in the presence and / or absence of the genetic features of the invention.
- the probe of the present invention may comprise a base sequence having complementarity to the part of the genome containing the mutation site of the present invention.
- Non-limiting examples of such probes include those containing a base sequence selected from SEQ ID NO: 55-64.
- SEQ ID NOs: 55, 57, 59, 61 and 63 are specific for alleles containing the mutations of the present invention
- SEQ ID NOs: 56, 58, 60, 62 and 64 include the mutations of the present invention Not specific to the allele.
- the presence of the genetic features of the invention can be detected by detection of an allele comprising a mutation of the invention and / or non-detection of an allele not comprising a mutation of the invention, the absence of the genetic features of the invention being It can be detected by non-detection of alleles containing the mutation of the present invention and / or detection of alleles not containing the mutation of the present invention.
- the probes of the invention preferably carry a label.
- the probe of the present invention has a base sequence selected from SEQ ID NOs: 55 to 64 and a label.
- the present invention further provides any one or more primer set selected from the group consisting of the above (1) to (5), (1 ′) to (5 ′) and (1 ′ ′) to (5 ′ ′) And a screening kit, optionally containing a restriction enzyme.
- a restriction enzyme contained in the kit is XbaI is there.
- the restriction enzyme contained in the kit is KpnI is there.
- the restriction enzyme contained in the kit is AflII is there.
- the restriction enzyme contained in the kit is PvuI is there.
- the restriction enzyme comprises XbaI
- the restriction enzyme comprises KpnI
- the restriction enzyme comprises AflII
- the restriction enzyme comprises PvuI.
- the present invention also provides a screening kit comprising a primer set capable of amplifying, by PCR, a region having a base sequence selected from the group consisting of SEQ ID NOs: 35 to 44, and the probe of the present invention.
- primer sets, probes and kits can be used to detect genetic features of the present invention, used in the screening methods of the present invention, and the like.
- these primer sets and kits contain instructions for detecting genetic features of the present invention and instructions for the screening method of the present invention, for example, a medium on which instructions for use and information on usage are recorded, for example, A flexible disc, a CD, a DVD, a Blu-ray disc, a memory card, a USB memory, etc. may be included.
- an extract from the plant of the present invention or seeds or leaves of the plant (for example, dried leaves or fresh leaves) is used.
- a process for producing a rebaudioside M-containing extract (hereinafter sometimes referred to as “the process for producing an extract of the present invention") is provided, which comprises the steps of: Furthermore, a method for producing rebaudioside M, which comprises the step of purifying rebaudioside M from the extract obtained by the method for producing an extract of the present invention (hereinafter sometimes referred to as "method for producing rebaudioside M of the present invention”) Is provided.
- the high rebaudioside M-containing Stevia plant of the present invention the high rebaudioside M-containing Stevia plant selected by the screening method of the present invention, or the high rebaudioside M-containing stevia plant produced by the method of the present invention
- a method of producing rebaudioside M, rebaudioside D or both comprising the step of obtaining an extract containing rebaudioside M, rebaudioside D or both from the body.
- Extracts containing rebaudioside M, rebaudioside D or both are prepared by reacting fresh leaves or dried leaves of the plant of the present invention with an appropriate solvent (aqueous solvent such as water or organic solvent such as alcohol, ether and acetone) It can be obtained by The extraction conditions can be referred to the methods described in Ohta et al., J. Appl. Glycosci., Vol. 57, No. 3 (2010) or WO 2010/038911, and the methods described in the examples below. .
- the extract containing rebaudioside M, rebaudioside D, or both is ethyl acetate or other organic solvent: water gradient, high performance liquid chromatography (HPLC), gas chromatography, time-of-flight mass spectrometry (Time-of-flight mass spectrometry (Time) Purification of rebaudioside M, rebaudioside D or both by using known methods such as -of-Flight mass spectrometry (TOF-MS), ultra high performance liquid chromatography (Ultra (High) Performance Liquid chromatography: UPLC), etc. Can.
- HPLC high performance liquid chromatography
- TOF-MS time-of-flight mass spectrometry
- Ultra (High) Performance Liquid chromatography: UPLC ultra high performance liquid chromatography
- the extract obtained by the method for producing the extract of the present invention contains rebaudioside M, rebaudioside D or both at a higher content than wild-type stevia species.
- the extract of the present invention is 300% or more, 400% or more, 500% or more, 600% or more, 700% or more, or 800% or more of rebaudioside M, rebaudioside D, or both as compared to the extract obtained from wild-type stevia species 900% or more, 1100% or more, 1200% or more, 1300% or more, 1400% or more, 1500% or more, 1600% or more, 1700% or more, 1800% or more, 1900% or more, 2000% or more, 2100% or more 2200% or more, 2300% or more, 2400% or more, 2500% or more, 2600% or more, 2700% or more, 2800% or more, 2900% or more, 3000% or more, 3100% or more, 3200% or more,
- the extract of the present invention thus obtained and / or rebaudioside M, rebaudioside D according to the present invention, rebaudioside D or both of them obtained by mixing rebaudioside M, rebaudioside D or both with other components It is possible to produce new pharmaceutical products, perfumes or food products with an increased content of rebaudioside M, rebaudioside D or both. Therefore, the present invention provides, as another embodiment, the extract of the present invention and / or rebaudioside M, rebaudioside D, or both of rebaudioside M of the present invention, rebaudioside M, rebaudioside D, or both and other components. And a process for producing a pharmaceutical product, a fragrance or a food or drink.
- the present invention provides a novel pharmaceutical product, flavor or food product having an increased content of rebaudioside M, rebaudioside D or both obtained by the above-mentioned production method.
- the food and drink mean beverages and food.
- the present invention provides a novel pharmaceutical, flavor, beverage or food product, and also provides a method for producing the pharmaceutical, flavor, beverage or food product.
- Example 1 Preparation of High Reb M Stevia Plants Introduction of breeding material and initial selection
- a commercial Stevia seed was sown and raised in August 2014, and about 30,000 individuals were selected according to the growth status and leaf form from October to March 2015 in the same year.
- selection was also carried out according to the total steviol glycoside (TSG) content, and 14 individuals with a TSG yield (total amount of measurable steviol glycosides obtained from unit leaf dry matter weight) of 20% or more were obtained.
- TSG total steviol glycoside
- High RebD and high RebM plants (3 individuals) and high TSG plants (6 individuals) selected by component analysis were subjected to a total of 53 combinations of hybridization tests as breeding mothers.
- the selected individuals were vegetatively propagated by cuttings in April 2015, and seedlings were established in June of the same year, and were cured by November until the same year to establish parent strains of multiple strains. After artificial mating was started from January 2016 to obtain hybrid seeds (F1 seeds) each having about 7,000 combinations, sowing and raising of F1 seeds obtained from the same year were performed.
- PCR was performed using the following primers, a restriction enzyme (XbaI) was added to the PCR product, an enzyme reaction was performed at 37 ° C., and treatment with the restriction enzyme was performed. After restriction enzyme treatment, electrophoresis was performed with a microchip electrophoresis apparatus LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- XbaI restriction enzyme
- electrophoresis was performed with a microchip electrophoresis apparatus LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the sequences of the primers are as follows.
- Fw primer 5'-AAGGTTCTTTATTTTTAAACT TATGTTAATTTATTGTATCTAG-3 '(SEQ ID NO: 1)
- Rv primer 5'-CCTTATGTACACATGCTACAC-3 '(SEQ ID NO: 2)
- the obtained PCR product (about 383 bp in length) was subjected to XbaI restriction enzyme treatment, and those which did not produce about 344 bp restriction enzyme-treated product (for example, SEQ ID NO: 23) were regarded as P01 positive.
- PCR was performed using the following primers, a restriction enzyme (KpnI) was added to the PCR product, an enzyme reaction was performed at 37 ° C., and treatment with the restriction enzyme was performed. After restriction enzyme treatment, electrophoresis was performed with a microchip electrophoresis apparatus LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the sequences of the primers are as follows.
- Fw primer 5'-TAATCATCCAAACCCTAATCTCGCCAACAACCGGGTAC-3 '(SEQ ID NO: 3)
- Rv primer 5'-GAGGAAGACATTGGCAACTC-3 '(SEQ ID NO: 4)
- the obtained PCR product (about 297 bp in length) was subjected to KpnI restriction enzyme treatment, and those which did not produce about 260 bp restriction enzyme-treated product (for example, SEQ ID NO: 26) were regarded as P02 positive.
- PCR was performed using the following primers, a restriction enzyme (AflII) was added to the PCR product, an enzyme reaction was performed at 37 ° C., and treatment with the restriction enzyme was performed. After restriction enzyme treatment, electrophoresis was performed with a microchip electrophoresis apparatus LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the sequences of the primers are as follows.
- Fw primer 5'-CGATGGTTTTTTGCTACATGAAAACCCTAGAAGACGAAACCCGCTTAA-3 '(SEQ ID NO: 5)
- Rv primer 5'-ACCAGCAATAATCCTTGAATTAG-3 '(SEQ ID NO: 6)
- the obtained PCR product (about 390 bp in length) was subjected to AflII restriction enzyme treatment, and a product which did not produce about 347 bp restriction enzyme treated product (eg, SEQ ID NO: 29) was regarded as P03 positive.
- P04 PCR was performed to detect the marker P04 using the following primers.
- the PCR product was electrophoresed on a microchip electrophoresis apparatus LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the sequences of the primers are as follows. Fw primer: 5'-CGCAAACACG TATACTAATC-3 '(SEQ ID NO: 7)
- Rv primer 5'-TTTAGCATGGTATGTACAAC-3 '(SEQ ID NO: 8)
- the one that generated only a PCR product of about 140 bp was designated as P04 positive.
- P05 For detection of the marker P05, PCR was performed using the following primers, a restriction enzyme (PvuI) was added to the PCR product, an enzyme reaction was performed at 37 ° C., and treatment with the restriction enzyme was performed. After restriction enzyme treatment, electrophoresis was performed with a microchip electrophoresis apparatus LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the sequences of the primers are as follows.
- Fw primer 5'-ATACAAAAACACAACCCATATGGTCAAATCAACCCATT CATGAGCGATC-3 '(SEQ ID NO: 9)
- Rv primer 5'-CCCTTGTAAATCCCATATGTAG-3 '(SEQ ID NO: 10)
- the obtained PCR product (about 288 bp in length) was subjected to PvuI restriction enzyme treatment, and those which did not produce about 240 bp restriction enzyme-treated product (for example, SEQ ID NO: 33) were regarded as P05 positive.
- rebaudiosides M and D can be provided more efficiently. Therefore, by containing rebaudiosides M and D in a sufficient amount, it is possible to provide high-quality pharmaceutical products, flavors or food products and the like.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
Abstract
Description
[1-1] 葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有非遺伝子組み換えステビア植物体。
[1-2] 葉に含まれる総ステビオール配糖体量に対し9.5%以上のレバウジオシドDをさらに含む、[1-1]に記載の植物体。
[1-3]
以下の(1)~(5)の少なくとも1つの遺伝的特徴を有する、[1-1]又は[1-2]に記載の植物体。
(1)配列番号35の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号37の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号39の41位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号42の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号43の50位に相当する位置の塩基がAであるアレルについてホモ接合性である。
[1-4]
P01~P05からなる群より選択される少なくとも一つの多型マーカーについて陽性である、[1-1]~[1-3]のいずれか一項に記載の植物体。
[1-5] [1-1]~[1-4]のいずれか一項に記載の植物体の種子、組織、組織培養物又は植物培養細胞。
[1-6] 胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルスである[1-5]に記載の組織、組織培養物又は植物培養細胞。
[1-7] [1-1]~[1-4]のいずれか一項に記載のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有ステビア植物体を作出する方法。
[1-8] 第2の植物体が[1-1]~[1-4]のいずれか一項に記載のステビア植物体である、[1-7]に記載の方法。
[1-9] [1-1]~[1-4]のいずれか一項に記載の植物体、[1-5]に記載の種子、組織、組織培養物又は細胞の抽出物。
[1-10] [1-9]に記載の抽出物を含む飲食品、甘味組成物、香料又は医薬品。
[1-11] [1-1]~[1-4]のいずれか一項に記載の植物体、[1-5]に記載の種子、組織、組織培養物又は細胞から抽出物を得る工程を含む、レバウジオシドM含有抽出物の製造方法。
[1-12] [1-11]に記載のレバウジオシドM含有抽出物からレバウジオシドMを精製する工程を含む、レバウジオシドMの製造方法。
[1-13] [1-11]に記載の方法により得られる抽出物及び/又は[1-12]に記載の方法により得られるレバウジオシドMと他の成分とを混合する工程を含む、飲食品、甘味組成物、香料又は医薬品の製造方法。
[1-14] 被験植物のゲノムから以下の(1)~(5)の少なくとも1つの遺伝的特徴の存在及び/又は不在を検出する工程を含む、高レバウジオシドM含有型ステビア植物体をスクリーニングする方法。
(1)配列番号35の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号37の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号39の41位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号42の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号43の50位に相当する位置の塩基がAであるアレルについてホモ接合性である。
[1-15] 被験植物のゲノムからP01~P05からなる群より選択される少なくとも一つの多型マーカーを検出する工程を含む、[1-14]に記載の方法。
[1-16] さらに、葉組織のレバウジオシドMの含有量を測定する工程を含む、[1-14]又は[1-15]に記載の方法。
[1-17]
(1)配列番号1における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号2における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(2)配列番号3における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号4における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(3)配列番号5における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号6における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(4)配列番号7における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号8における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、あるいは
(5)配列番号9における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号10における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
からなる群より選択されるいずれか一つ以上のプライマーセットであり、前記任意の連続する15塩基以上の配列は各プライマーの3‘末端に位置する、前記プライマーセット。
[1-18]
[1-17]に記載のプライマーセットと、場合により制限酵素とを含むキットであり、
前記プライマーセットが配列番号1における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素XbaIを含み、
前記プライマーセットが配列番号3における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素KpnIを含み、
前記プライマーセットが配列番号5における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素AflIIを含み、
前記プライマーセットが配列番号9における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素PvuIを含む、
前記キット。
[1-19]
検出可能な標識と結合していてもよい、配列番号55~64のいずれか一つに示す塩基配列を含むプローブ。
[1-20]
蛍光標識、色素又は結合部分を有する[1-19]に記載のプローブ。
[1-21] P01~P05からなる群より選択される少なくとも一つの多型マーカーを検出することを目的として被験植物のゲノムDNAに対し[1-17]に記載のプライマーセットを用いてPCR増幅を行う工程、及び前記多型マーカーがP01~P03及びP05からなる群より選択される少なくとも一つである場合、前記PCR増幅により得られたPCR産物を制限酵素で処理し、制限酵素処理産物を検出する工程を含む、高レバウジオシドM含有非遺伝子組み換えステビア植物体のスクリーニング方法。
[1-22] 前記制限酵素がXbaI、KpnI、AflII及びPvuIからなる群より選択される少なくとも一つである、[1-21]に記載の方法。
[1-23] 前記多型マーカーがP02及びP05を含む、[1-21]に記載の方法。
[1-24] 前記制限酵素がKpnI及びPvuIを含む、[1-23]に記載の方法。
[1-25] スクリーニングにより得られる植物体が葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含む、[1-21]~[1-24]のいずれか一項に記載の方法。
本発明はまた、以下を提供する。
[2-1] 乾燥葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有非遺伝子組み換えステビア植物体。
[2-2] 乾燥葉に含まれる総ステビオール配糖体量に対し9.5%以上のレバウジオシドDをさらに含む、前記[2-1]に記載の植物体。
[2-3]
P01、P02、P03、P04及びP05からなる群より選択される少なくとも一つの多型マーカーについて陽性である、前記[2-1]又は[2-2]に記載の植物体。
[2-4] 前記[2-1]~[2-3]のいずれか一つに記載の植物体の種子。
[2-5] 前記[2-1]~[2-3]のいずれか一つに記載の植物体の乾燥葉。
[2-6] 前記[2-1]~[2-3]のいずれか一つに記載の植物体の組織培養物又は植物培養細胞。
[2-7] 胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルスである前記[2-6]に記載の組織培養物又は植物培養細胞。
[2-8] 前記[2-1]~[2-3]のいずれか一つに記載のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、乾燥葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有ステビア植物体を作出する方法。
[2-9] 第2の植物体が前記[2-1]~[2-3]のいずれか一つに記載のステビア植物体である、前記[2-8]に記載の方法。
[2-10] 前記[2-1]~[2-3]のいずれか一つに記載の植物体、前記[2-4]に記載の種子又は前記[2-5]に記載の乾燥葉の抽出物。
[2-11] 前記[2-10]に記載の抽出物を含む飲食品、甘味組成物、香料又は医薬品。
[2-12] 前記[2-1]~[2-3]のいずれか一つに記載の植物体、前記[2-4]に記載の種子又は前記[2-5]に記載の乾燥葉から抽出物を得る工程を含む、レバウジオシドM含有抽出物の製造方法。
[2-13] 前記[2-12]に記載のレバウジオシドM含有抽出物からレバウジオシドMを精製する工程を含む、レバウジオシドMの製造方法。
[2-14] 前記[2-12]に記載の方法により得られる抽出物及び/又は前記[2-13]に記載の方法により得られるレバウジオシドMと他の成分とを混合する工程を含む、飲食品、甘味組成物、香料又は医薬品の製造方法。
[2-15] 被験植物のゲノムからP01、P02、P03、P04及びP05からなる群より選択される少なくとも一つの多型マーカーを検出する工程を含む、高レバウジオシドM含有型ステビア植物体をスクリーニングする方法。
[2-16] さらに、葉組織のレバウジオシドMの含有量を測定する工程を含む、前記[2-15]に記載の方法。
[2-17]
(1)配列番号1における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号2における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(2)配列番号3における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号4における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(3)配列番号5における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号6における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(4)配列番号7における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号8における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、あるいは
(5)配列番号9における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号10における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
からなる群より選択されるいずれか一つ以上のプライマーセットであり、前記任意の連続する15塩基以上の配列は各プライマーの3‘末端に位置する、前記プライマーセット。
[2-18]
前記[2-17]に記載の(1)~(5)より選択される少なくとも1つのプライマーセットと制限酵素を含むキットであり、
前記プライマーセットが(1)の場合は、前記制限酵素はXbaIであり、
前記プライマーセットが(2)の場合は、前記制限酵素はKpnIであり、
前記プライマーセットが(3)の場合は、前記制限酵素はAflIIであり、
前記プライマーセットが(5)の場合は、前記制限酵素はPvuIである、
前記キット。
[2-19]
検出可能な標識と結合していてもよい、配列番号1~10のいずれか一つに示す塩基配列を含むプローブ。
[2-20]
蛍光標識、色素又は結合部分を有する前記[2-19]に記載のプローブ。
[2-21] P01、P02、P03、P04及びP05からなる群より選択される少なくとも一つの多型マーカーを検出することを目的として被験植物のゲノムDNAに対し前記[2-17]に記載のプライマーセットを用いてPCR増幅を行う工程、及び
前記多型マーカーがP01、P02、P03及びP05からなる群より選択される少なくとも一つである場合、前記PCR増幅により得られたPCR産物を制限酵素で処理し、制限酵素処理産物を検出する工程、
を含む、高レバウジオシドM含有非遺伝子組み換えステビア植物体のスクリーニング方法。
[2-22] 前記制限酵素がXbaI、KpnI、AflII及びPvuIからなる群より選択される少なくとも一つである、前記[2-21]に記載の方法。
[2-23] 前記多型マーカーがP02及びP05である、前記[2-21]に記載の方法。
[2-24] 前記制限酵素がKpnI及びPvuIである、前記[2-23]に記載の方法。
[2-25] スクリーニングにより得られる植物体が乾燥葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含む、前記[2-21]~[2-24]のいずれか一つに記載の方法。
なお、本明細書において引用した全ての文献、及び公開公報、特許公報その他の特許文献は、参照として本明細書に組み込むものとする。また、本明細書は、2017年10月12日に出願された本願優先権主張の基礎となる日本国特許出願(特願2017-198515号)の明細書及び図面に記載の内容を包含する。
本発明は、葉(例えば、乾燥葉又は新鮮葉)に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有非遺伝子組み換えステビア植物体(以下、「本発明の植物体」又は「本発明のステビア植物体」と称する場合がある)を提供する。
本発明のステビア植物体は、野生種のステビア植物体から派生した種であるが、レバウジオシドMが高くなるように遺伝子に変異が生じたものである。かつ当該遺伝子の変異は非遺伝子組換え的に生じるものである(後述)。
本発明において、高レバウジオシドM含有非遺伝子組み換えステビア植物体のうち、葉(例えば、乾燥葉又は新鮮葉)に含まれる総ステビオール配糖体量に対し2~4.6%のレバウジオシドMを含むことを特徴とするステビア植物体を高レバウジオシドM含有非遺伝子組み換えステビア植物体と称することがあり、4.7%以上のレバウジオシドMを含むことを特徴とするステビア植物体は超高レバウジオシドM含有非遺伝子組み換えステビア植物体と称することもある。
ここで、レバウジオシドMとDとの含量の組み合わせは特に限定されず、任意である。
好ましくは、本発明の植物体は、乾燥葉100g中に1.03g以上のレバウジオシドMと1.1g以上のレバウジオシドDを含む。
また、本発明のステビア植物体は、葉(例えば、乾燥葉又は新鮮葉)中のレバウジオシドM(RebM)及びレバウジオシドD(RebD)の含量をステビオール配糖体総量に対する比率として(RebD+RebM)/TSG%で表した場合、(RebD+RebM)/TSGの値の下限が14%以上、16%以上、18%以上、20%以上、22%以上、24%以上、26%以上、28%以上、30%以上、32%以上、34%以上、36%以上、38%以上であることを特徴とする。一方、(RebD+RebM)/TSGの値の上限は、18%以下、20%以下、22%以下、24%以下、26%以下、28%以下、30%以下、32%以下、34%以下、36%以下、38%以下、40%以下であることを特徴とする。この下限と上限の組み合わせは、上限値が下限値を上回る組み合わせであれば特に限定されないが、好ましくは14%以上かつ40%以下、あるいは16%以上かつ40%以下である。
(1)配列番号35の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号37の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号39の41位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号42の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号43の50位に相当する位置の塩基がAであるアレルについてホモ接合性である。
ここでは簡潔のため遺伝的特徴(1)を例に説明したが、遺伝的特徴(2)~(5)についても同様である。
特定の態様において、「配列番号37に相当する塩基配列からなる部分」には、例えば、配列番号47の塩基配列を含むフォワードプライマーと、配列番号48の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号39に相当する塩基配列からなる部分」には、例えば、配列番号49の塩基配列を含むフォワードプライマーと、配列番号50の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号42に相当する塩基配列からなる部分」には、例えば、配列番号51の塩基配列を含むフォワードプライマーと、配列番号52の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号43に相当する塩基配列からなる部分」には、例えば、配列番号53の塩基配列を含むフォワードプライマーと、配列番号54の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号37の40位に相当する位置の塩基がTであるアレル」は、配列番号57、67又は77の塩基配列を含む。
特定の態様において、「配列番号39の41位に相当する位置の塩基がCであるアレル」は、配列番号59、69又は79の塩基配列を含む。
特定の態様において、「配列番号42の55~72位に相当する部分が欠失しているアレル」は、配列番号61、71又は81の塩基配列を含む。
特定の態様において、「配列番号43の50位に相当する位置の塩基がAであるアレル」は、配列番号63、73又は83の塩基配列を含む。
また、(1)配列番号35の44位に相当する位置におけるAからTへの変異、(2)配列番号37の40位に相当する位置におけるCからTへの変異、(3)配列番号39の41位に相当する位置におけるGからCへの変異、(4)配列番号42の55~72位に相当する部分の欠失、及び(5)配列番号43の50位に相当する位置におけるGからAへの変異からなる群から選択される変異を、「本発明の多型」又は「本発明の変異」と称することがある。
ここで多型マーカーはP01~P05からなる群より選択される少なくとも一つである。
P02について陽性とは、候補植物体のゲノムDNAに対し、配列番号3に示す塩基配列を有するフォワードプライマー及び配列番号4に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(297bp長)(例えば、配列番号24又は25)に対しKpnI制限酵素処理を行っても約297bp長のバンド(例えば、配列番号24)しか得られないことを意味する。反対に、約258bpの制限酵素処理産物(例えば、配列番号26)を生じる場合、その候補植物体はP02陰性となる。
P03について陽性とは、候補植物体のゲノムDNAに対し、配列番号5に示す塩基配列を有するフォワードプライマー及び配列番号6に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(約390bp長)(例えば、配列番号27又は28)に対しAflII制限酵素処理を行っても約390bp長のバンド(例えば、配列番号27)しか得られないことを意味する。反対に、約347bpの制限酵素処理産物(例えば、配列番号29)を生じる場合、その候補植物体はP03陰性となる。
P05について陽性とは、候補植物体のゲノムDNAに対し、配列番号9に示す塩基配列を有するフォワードプライマー及び配列番号10に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(約288bp長)(例えば、配列番号31又は32)に対しPvuI制限酵素処理を行っても約288bp長のバンド(例えば、配列番号31)しか得られないことを意味する。反対に、約240bpの制限酵素処理産物(例えば、配列番号33)を生じる場合、その候補植物体はP05陰性となる。
上記bp長に関し、「約」とは、±5bpを意味する。制限酵素処理は、使用する各制限酵素の販売元が推奨する条件に従って行うことができる。
上記遺伝的特徴(例えば、上記多型マーカー陽性の多型)は、高レバウジオシドM含有及び/又は高レバウジオシドD含有という表現型と統計学上の相関関係を有することが実施例において確認されている。
さらに、このようにして得られた抽出液に対し、酢酸エチルその他の有機溶媒:水の勾配、高速液体クロマトグラフィー(High Performance Liquid Chromatography:HPLC)、ガスクロマトグラフィー、飛行時間型質量分析(Time-of-Flight mass spectrometry:TOF-MS)、超高性能液体クロマトグラフィー(Ultra (High) Performance Liquid chromatography:UPLC)等の公知の方法を用いることによりレバウジオシドMを精製することができる。
本発明は、別の実施態様において、本発明のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、葉(例えば、乾燥葉又は新鮮葉)に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有ステビア植物体を作出する方法(以下、「本発明の作出方法」と称する場合がある)を提供する。
当該方法により作出される「葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有ステビア植物体」は、本発明の植物体と同じ表現型と遺伝的性質を有する。
ここで、レバウジオシドMとDとの含量の組み合わせは特に限定されず、任意である。
好ましくは、本発明の作出方法によって得られた植物体は、乾燥葉100g中に1.03g以上のレバウジオシドMと1.1g以上のレバウジオシドDを含む。
また、本発明の作出方法によって得られた植物体は、葉(例えば、乾燥葉又は新鮮葉)中のレバウジオシドM(RebM)及びレバウジオシドD(RebD)の含量をステビオール配糖体総量に対する比率として(RebD+RebM)/TSG%で表した場合、(RebD+RebM)/TSGの値の下限が14%以上、16%以上、18%以上、20%以上、22%以上、24%以上、26%以上、28%以上、30%以上、32%以上、34%以上、36%以上、38%以上であることを特徴とする。一方、(RebD+RebM)/TSGの値の上限は、18%以下、20%以下、22%以下、24%以下、26%以下、28%以下、30%以下、32%以下、34%以下、36%以下、38%以下、40%以下であることを特徴とする。この下限と上限の組み合わせは、上限値が下限値を上回る組み合わせであれば特に限定されないが、好ましくは14%以上かつ40%以下、あるいは16%以上かつ40%以下である。
(1)配列番号35の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号37の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号39の41位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号42の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号43の50位に相当する位置の塩基がAであるアレルについてホモ接合性である。
かかる遺伝的特徴は、本発明者らが開発した多型マーカーを用いて「多型マーカー陽性」のものとして検出することが可能である。
ここで多型マーカーはP01~P05からなる群より選択される少なくとも一つである。
P02について陽性とは、候補植物体のゲノムDNAに対し、配列番号3に示す塩基配列を有するフォワードプライマー及び配列番号4に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(297bp長)(例えば、配列番号24又は25)に対しKpnI制限酵素処理を行っても約297bp長のバンド(例えば、配列番号24)しか得られないことを意味する。反対に、約258bpの制限酵素処理産物(例えば、配列番号26)を生じる場合、その候補植物体はP02陰性となる。
P03について陽性とは、候補植物体のゲノムDNAに対し、配列番号5に示す塩基配列を有するフォワードプライマー及び配列番号6に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(約390bp長)(例えば、配列番号27又は28)に対しAflII制限酵素処理を行っても約390bp長のバンド(例えば、配列番号27)しか得られないことを意味する。反対に、約347bpの制限酵素処理産物(例えば、配列番号29)を生じる場合、その候補植物体はP03陰性となる。
P05について陽性とは、候補植物体のゲノムDNAに対し、配列番号9に示す塩基配列を有するフォワードプライマー及び配列番号10に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(約288bp長)(例えば、配列番号31又は32)に対しPvuI制限酵素処理を行っても約288bp長のバンド(例えば、配列番号31)しか得られないことを意味する。反対に、約240bpの制限酵素処理産物(例えば、配列番号33)を生じる場合、その候補植物体はP05陰性となる。
上記bp長に関し、「約」とは、±5bpを意味する。制限酵素処理は、使用する各制限酵素の販売元が推奨する条件に従って行うことができる。
一般に、植物細胞は、培養の間に変異を伴うことがあるため、より安定した形質維持のために植物個体に戻すことが好ましい。
なお、本発明の植物体は非遺伝子組み換えステビア植物体であるが、本発明の植物体を宿主として事後的に遺伝子組み換え(例えばゲノム編集等により)を行って得られた植物体(例えば、本発明の植物体を宿主として遺伝子組み換えを行って、さらに別の形質を付加した植物体)も、本発明の範囲から除外されるものではない。
本発明の植物体及び本発明の植物体と同じ表現型と遺伝的性質を有する植物体は、当該植物体の組織から本発明の遺伝的特徴を検出することによりスクリーニングすることができる。ここで、「スクリーニング」とは、本発明の植物体とそれ以外の植物体とを識別し、本発明の植物体を選択することを意味する。
したがって、本発明は、別の実施形態として、被験植物のゲノムから以下の(1)~(5)の少なくとも1つの遺伝的特徴の存在及び/又は不在を検出する工程を含む、高レバウジオシドM含有型ステビア植物体をスクリーニングする方法(以下、「本発明のスクリーニング方法」と称する場合がある)を提供する。
(1)配列番号35の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号37の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号39の41位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号42の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号43の50位に相当する位置の塩基がAであるアレルについてホモ接合性である。
本発明のスクリーニング方法は、上記(1)~(5)の少なくとも1つの遺伝的特徴の存在が検出された植物体を被験植物の中から選択する工程をさらに含んでもよい。
(A)配列番号35の44位に相当する位置の塩基がTであるアレル、
(B)配列番号37の40位に相当する位置の塩基がTであるアレル、
(C)配列番号39の41位に相当する位置の塩基がCであるアレル、
(D)配列番号42の55~72位に相当する部分が欠失しているアレル、及び
(E)配列番号43の50位に相当する位置の塩基がAであるアレル
からなる群から選択されるアレルの存在の検出、及び/又は、
(a)配列番号35の44位に相当する位置の塩基がAであるアレル、
(b)配列番号37の40位に相当する位置の塩基がCであるアレル、
(c)配列番号39の41位に相当する位置の塩基がGであるアレル、
(d)配列番号42の55~72位に相当する部分が欠失していないアレル、及び
(e)配列番号43の50位に相当する位置の塩基がGであるアレル
からなる群から選択されるアレルの不在の検出
により決定することができる。
(A)配列番号35の44位に相当する位置の塩基がTであるアレル、
(B)配列番号37の40位に相当する位置の塩基がTであるアレル、
(C)配列番号39の41位に相当する位置の塩基がCであるアレル、
(D)配列番号42の55~72位に相当する部分が欠失しているアレル、及び
(E)配列番号43の50位に相当する位置の塩基がAであるアレル
からなる群から選択されるアレルの不在の検出、及び/又は、
(a)配列番号35の44位に相当する位置の塩基がAであるアレル、
(b)配列番号37の40位に相当する位置の塩基がCであるアレル、
(c)配列番号39の41位に相当する位置の塩基がGであるアレル、
(d)配列番号42の55~72位に相当する部分が欠失していないアレル、及び
(e)配列番号43の50位に相当する位置の塩基がGであるアレル
からなる群から選択されるアレルの存在の検出
により決定することができる。
あるいは、本発明の多型とプライマー配列とは重複させず、かつ本発明の遺伝子変異をPCR増幅させることが可能なようにプライマー配列を設計し、増幅されたヌクレオチド断片の塩基配列をシーケンスすることにより、本発明の遺伝的特徴を検出することができる。
PCR及びアガロースゲル電気泳動については、以下を参照:Sambrook, Fritsch and Maniatis, ”Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press。
シークエンス法とは、変異を含む領域をPCRにて増幅させ、Dye Terminatorなどを用いてDNA配列をシークエンスすることで、変異の有無を解析する方法である(Sambrook, Fritsch and Maniatis, ”Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press)。
DNAマイクロアレイは、ヌクレオチドプローブの一端が支持体上にアレイ状に固定されたものであり、DNAチップ、Geneチップ、マイクロチップ、ビーズアレイ等を包含する。本発明の多型と相補的な配列を含むプローブを用いることで、網羅的に本発明の多型の有無を検出することができる。DNAチップなどのDNAマイクロアレイアッセイとしてはGeneChipアッセイが挙げられる(Affymetrix社;米国特許第6,045,996号、同第5,925,525号、及び同第5,858,659号参照)。GeneChip技術は、チップに貼り付けたオリゴヌクレオチドプローブの小型化高密度マイクロアレイを利用するものである。
TILLING(Targeting Induced Local Lesions IN Genomes)法とは、変異導入した突然変異体集団のゲノム中の変異ミスマッチをPCR増幅とCEL Iヌクレアーゼ処理によってスクリーニングする方法である。
P01~P05の陽性の検出方法については既に述べた通りである。
この態様において、本発明のスクリーニング方法は、本発明の多型マーカー陽性が検出された植物体を被験植物の中から選択する工程をさらに含んでもよい。
前記PCR増幅により得られたPCR産物を制限酵素で処理し、制限酵素処理産物を検出する工程、
を含む、高レバウジオシドM含有非遺伝子組み換えステビア植物体のスクリーニング方法が提供される。
(1)配列番号1に示す塩基配列を含むフォワードプライマー及び配列番号2に示す塩基配列を含むリバースプライマーを含む、プライマーセット、
(2)配列番号3に示す塩基配列を含むフォワードプライマー及び配列番号4に示す塩基配列を含むリバースプライマーを含む、プライマーセット、
(3)配列番号5に示す塩基配列を含むフォワードプライマー及び配列番号6に示す塩基配列を含むリバースプライマーを含む、プライマーセット、
(4)配列番号7に示す塩基配列を含むフォワードプライマー及び配列番号8に示す塩基配列を含むリバースプライマーを含む、プライマーセット、又は
(5)配列番号9に示す塩基配列を含むフォワードプライマー及び配列番号10に示す塩基配列を含むリバースプライマーを含む、プライマーセット。 PCR増幅の条件についてはすでに述べたとおりである。
(1’’)配列番号1における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号2における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(2’’)配列番号3における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号4における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(3’’)配列番号5における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号6における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(4’’)配列番号7における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号8における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、あるいは
(5’’)配列番号9における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号10における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット。 このようなプライマーは、前記任意の連続する15塩基以上の配列が3‘側末端に存在すれば、15~50塩基長、20~45塩基長、30~65塩基長の長さにあってもよい。
(i)被験ステビア植物のゲノムから、本発明の遺伝的特徴を検出する工程、
(ii)本発明の遺伝的特徴が検出された被験ステビア植物組織のRebMの含有量を測定する工程、
(iii)本発明の遺伝的特徴が検出された被験ステビア植物体のうち、RebMの含有量が高い個体を選択する工程、
(iv)選択したRebMの含有量が高い個体を他のステビア植物体と交配する工程、
(v)交配により得られた子植物体のゲノムから、本発明の遺伝的特徴を検出する工程、
(vi)本発明の遺伝的特徴が検出された子植物組織のRebMの含有量を測定する工程、
(vii)本発明の遺伝的特徴が検出された子植物体のうち、RebMの含有量が高い個体を選択する工程。
本発明のスクリーニング方法において、被験ステビア植物体は、突然変異誘発処理を行ったステビア植物及びその子孫植物を含んでもよい。突然変異誘発処理については、本発明の植物体の項に記載したとおりであり、変異誘発剤による処理や、放射線又は光線の照射による処理等を含む。
当該キットにおいて、(1)、(1’)及び(1’’)からなる群より選択される選択されるいずれか一つ以上のプライマーセットを用いる場合、前記キットに含まれる制限酵素はXbaIである。
当該キットにおいて、(2)、(2’)及び(2’’)からなる群より選択される選択されるいずれか一つ以上のプライマーセットを用いる場合、前記キットに含まれる制限酵素はKpnIである。
当該キットにおいて、(3)、(3’)及び(3’’)からなる群より選択される選択されるいずれか一つ以上のプライマーセットを用いる場合、前記キットに含まれる制限酵素はAflIIである。
当該キットにおいて、(5)、(5’)及び(5’’)からなる群より選択される選択されるいずれか一つ以上のプライマーセットを用いる場合、前記キットに含まれる制限酵素はPvuIである。
前記プライマーセットが配列番号1における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、前記制限酵素はXbaIを含み、
前記プライマーセットが配列番号3における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、前記制限酵素はKpnIを含み、
前記プライマーセットが配列番号5における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、前記制限酵素はAflIIを含み、
前記プライマーセットが配列番号9における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、前記制限酵素はPvuIを含む。
本発明のさらなる態様において、本発明の植物体、又は当該植物体の種子若しくは葉(例えば、乾燥葉又は新鮮葉)から抽出物を得る工程を含む、レバウジオシドM含有抽出物の製造方法(以下、「本発明の抽出物の製造方法」と称する場合がある)が提供される。さらに、本発明の抽出物の製造方法により得られた抽出物からレバウジオシドMを精製する工程を含む、レバウジオシドMの製造方法(以下、「本発明のレバウジオシドMの製造方法」と称する場合がある)が提供される。
具体的には、本発明の高レバウジオシドM含有型ステビア植物体、本発明のスクリーニング方法により選別された高レバウジオシドM含有型ステビア植物体又は本発明の方法により製造された高レバウジオシドM含有型ステビア植物体からレバウジオシドM、レバウジオシドD又はその両方を含む抽出物を得る工程を含む、レバウジオシドM、レバウジオシドD又はその両方の製造方法が提供される。
レバウジオシドM、レバウジオシドD又はその両方を含む抽出物は、本発明の植物体の新鮮葉又は乾燥葉に適切な溶媒(水等の水性溶媒又はアルコール、エーテル及びアセトン等の有機溶媒)を反応させることにより得ることができる。抽出条件等はOhta et al.、J. Appl. Glycosci.、 Vol. 57、 No. 3 (2010)又はWO2010/038911に記載の方法や、後述の実施例に記載の方法を参照することができる。
また、レバウジオシドM、レバウジオシドD又はその両方を含む抽出物を酢酸エチルその他の有機溶媒:水の勾配、高速液体クロマトグラフィー(High Performance Liquid Chromatography:HPLC)、ガスクロマトグラフィー、飛行時間型質量分析(Time-of-Flight mass spectrometry:TOF-MS)、超高性能液体クロマトグラフィー(Ultra (High) Performance Liquid chromatography:UPLC)等の公知の方法を用いることによりレバウジオシドM、レバウジオシドD又はその両方を精製することができる。
本発明の抽出物は、野生型ステビア種から得られた抽出物と比べレバウジオシドM、レバウジオシドD又はその両方を300%以上、400%以上、500%以上、600%以上、700%以上、800%以上、900%以上、1100%以上、1200%以上、1300%以上、1400%以上、1500%以上、1600%以上、1700%以上、1800%以上、1900%以上、2000%以上、2100%以上、2200%以上、2300%以上、2400%以上、2500%以上、2600%以上、2700%以上、2800%以上、2900%以上、3000%以上、3100%以上、3200%以上、3300%以上、3400%以上、3500%以上、3600%以上、3700%以上、3800%以上、3900%以上、4000%以上、4100%以上、4200%以上、4300%以上、4400%以上、4500%以上、4600%以上、4700%以上、4800%以上、4900%以上、5000%以上高い含量で含んでいてもよい。ここで、本発明の抽出物と、野生型ステビア種から得られた抽出物は、同じ方法で得られたものであってよい。
1.育種素材の導入及び初期選抜
2014年8月に市販ステビア種子を播種、育苗し、同年10月~2015年3月までの間に約3、000個体について生育状況及び葉形態によって選抜を行った。2015年4月に得られた115個体についてLC-MS/MSを用いた定量分析により各ステビオール配糖体の含有量及び含有率を測定し、RebD及びRebMの含有率が高い3個体(2成分合計でTSGに占める割合が20%以上の個体)を選抜した。同時に、総ステビオール配糖体(TSG)含量によっても選抜も実施し、TSG収率(単位リーフ乾物重より得られる測定可能なステビオール配糖体の総量)が20%以上の14個体を得た。
上記で得られた115個体より、生育状況が良い高RebA型の5個体を選抜し、2015年1月より個体間もしくは個体内で人工授粉を行い、同年3月に集団採種を実施して自殖第一代(S1種子)を得た。さらに、これらS1種子を播種・育苗し、105個体のS1個体群を得た。2015年6月、これらのS1個体群を個体別に育成し、個体内での人工授粉により自殖第二代(S2種子)を得た。得られたS2種子は得られたS1個体ごとに系統として区別し105系統のS2個体群を得た。その後、得られたS2個体の生育状況を確認し、生育良好な個体について各個体の葉を4枚サンプリングし、LC-MS/MSを用いてステビオール配糖体量の定量分析を行った。得られた分析結果より、RebD含量、RebM含量及びTSG量を算出し、葉100g当たりのRebD含量+RebM含量の合算値が2g(=2%)を超える個体を優良個体として選抜した。
成分分析によって選抜した高RebDかつ高RebM植物体(3個体)、及び高TSG植物体(6個体)を育種母本として合計53組合せの交雑試験に供した。上記選抜個体は2015年4月に挿し木によって栄養繁殖を行い同年6月に苗を確立し、同年11月までの間に養生してそれぞれ複数株の親株を確立した。2016年1月より人工交配を開始し、各組合せ1、000粒程度の雑種種子(F1種子)を得たのち、同年3月より得られたF1種子の播種・育苗を行った。その後、得られたF1個体の生育状況を確認し、生育良好な個体について各個体の葉を4枚サンプリングし、LC-MS/MSを用いてステビオール配糖体量の定量分析を行った。得られた分析結果より、RebD含量、RebM含量及びTSG量を算出し、RebD含量+RebM含量の合算値が2g/100g(=2%)を超える個体を優良個体として選抜した。
初期選抜で得られた10個体を用いて遺伝マーカーの作製を行った。2015年6月、RebD+RebM含量率の合算値に基づいて高(29.16%以上)・低(6.06%以下)の2グループに分類し、二次代謝物の生合成経路を活性化することで知られているWRKYコード領域及びWD40コード領域において各グループに共通する多型探索を実施、特定の一塩基多型(SNP)を取得した。得られたSNPに基づいてプライマー設計と制限酵素の選択を行い、特定のSNPの識別を可能とする多型マーカー(1)~(5)を確立した。
マーカーP01の検出には以下のプライマーを用いてPCRを行い、PCR産物に制限酵素(XbaI)を添加し、37℃で酵素反応を行い、制限酵素による処理を行った。制限酵素処理後、マイクロチップ型電気泳動装置LabChip GX Touch HTにより電気泳動を行い、電気泳動後のバンドパターンによってマーカーの識別を行った。
プライマーの配列は以下のとおり。
Fwプライマー:5’-AAGGTTCTTTATTTTTAAACTTATGTTAATTTATTGTATCTAG-3’(配列番号1)
Rvプライマー:5’-CCTTATGTACACATGCTACAC-3’(配列番号2)
得られたPCR産物(約383bp長)に対しXbaI制限酵素処理を行い、約344bpの制限酵素処理産物(例えば、配列番号23)を生じなかったものをP01陽性とした。
マーカーP02の検出には以下のプライマーを用いてPCRを行い、PCR産物に制限酵素(KpnI)を添加し、37℃で酵素反応を行い、制限酵素による処理を行った。制限酵素処理後、マイクロチップ型電気泳動装置LabChip GX Touch HTにより電気泳動を行い、電気泳動後のバンドパターンによってマーカーの識別を行った。
プライマーの配列は以下のとおり。
Fwプライマー:5’-TAATCATCCAAACCCTAATCTCGCCAAACAACCGGGTAC-3’(配列番号3)
Rvプライマー:5’-GAGGAAGACATTGGCAACTC-3’(配列番号4)
得られたPCR産物(約297bp長)に対しKpnI制限酵素処理を行い、約260bpの制限酵素処理産物(例えば、配列番号26)を生じなかったものをP02陽性とした。
マーカーP03の検出には以下のプライマーを用いてPCRを行い、PCR産物に制限酵素(AflII)を添加し、37℃で酵素反応を行い、制限酵素による処理を行った。制限酵素処理後、マイクロチップ型電気泳動装置LabChip GX Touch HTにより電気泳動を行い、電気泳動後のバンドパターンによってマーカーの識別を行った。
プライマーの配列は以下のとおり。
Fwプライマー:5’-CGATGGTTTTTGCTACATGAAAACCCTAGAAGACGAAACCCGCTTAA-3’(配列番号5)
Rvプライマー:5’-ACCAGCAATAATCCTTGAATTAG-3’(配列番号6)
得られたPCR産物(約390bp長)に対しAflII制限酵素処理を行い、約347bpの制限酵素処理産物(例えば、配列番号29)を生じなかったものをP03陽性とした。
マーカーP04の検出には以下のプライマーを用いてPCRを行った。PCR産物をマイクロチップ型電気泳動装置LabChip GX Touch HTで電気泳動させ、電気泳動後のバンドパターンによってマーカーの識別を行った。
プライマーの配列は以下のとおり。
Fwプライマー:5’-CGCAAACACGTATACTAATC-3’(配列番号7)
Rvプライマー:5’-TTTAGCATGGTATGTACAAC-3’(配列番号8)
約140bpのPCR産物のみ(例えば、配列番号30)を生じたものをP04陽性とした。
マーカーP05の検出には以下のプライマーを用いてPCRを行い、PCR産物に制限酵素(PvuI)を添加し、37℃で酵素反応を行い、制限酵素による処理を行った。制限酵素処理後、マイクロチップ型電気泳動装置LabChip GX Touch HTにより電気泳動を行い、電気泳動後のバンドパターンによってマーカーの識別を行った。
プライマーの配列は以下のとおり。
Fwプライマー:5’-ATACAAAAACACAACCCATATGGTCAAATCAACCCATTCATGAGCGATC-3’(配列番号9)
Rvプライマー:5’-CCCTTGTAAATCCCATATGTAG-3’(配列番号10)
得られたPCR産物(約288bp長)に対しPvuI制限酵素処理を行い、約240bpの制限酵素処理産物(例えば、配列番号33)を生じなかったものをP05陽性とした。
上記で確立した多型マーカーと第I個体群を用いて、マーカーの検証実験を実施した。第I個体群192個体の成分分析を行い、RebM含量値に基づいて、上位8個体(0.35%以上)・下位8個体(0.12%以下)を選抜し、上記のとおりマーカー検定を行った。その結果、RebM含量が高い上位8個体のみが目的の多型を陽性に持つ個体として選抜された(図1)。
第II個体群についても同様に検証実験を行った。第II個体群137個体の成分分析を行い、RebM含量値に基づいて、上位8個体(0.24%以上)・下位8個体(0.01%以下)を選抜し、マーカー検定を行った。その結果、RebM含量が高い上位8個体のみが目的の多型を持つ個体として選抜された(図2)。図1及び2では高RebM表現型を有する個体にのみ目的サイズのバンドが生じていることが分かる。
遺伝マーカーの検証時に用いた2つの分離集団、第I及び第II個体群について、さらなる検証のために個体数を増加して実験を行った。上記の個体数を含めてそれぞれ、62個体、109個体を用いた。RebM含量に基づいて0.2%以上、0.1%以上~0.2%未満、0%以上~0.1%未満の3群に分割し、マーカー検定を行った結果、0.2%以上群が本マーカーにより優先的に検出される結果となり、陽性個体の出現頻度が群間で統計的に有意に異なることが証明された(カイ二乗検定による適合度検定、帰無仮説はマーカー検定結果と表現型が紐づかず頻度分布が均等であると仮定。検定結果は下表を参照)。
Claims (25)
- 葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有非遺伝子組み換えステビア植物体。
- 葉に含まれる総ステビオール配糖体量に対し9.5%以上のレバウジオシドDをさらに含む、請求項1に記載の植物体。
- 以下の(1)~(5)の少なくとも1つの遺伝的特徴を有する、請求項1又は2に記載の植物体。
(1)配列番号35の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号37の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号39の41位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号42の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号43の50位に相当する位置の塩基がAであるアレルについてホモ接合性である。 - P01~P05からなる群より選択される少なくとも一つの多型マーカーについて陽性である、請求項1~3のいずれか一項に記載の植物体。
- 請求項1~4のいずれか一項に記載の植物体の種子、組織、組織培養物又は植物培養細胞。
- 胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルスである請求項5記載の組織、組織培養物又は植物培養細胞。
- 請求項1~4のいずれか一項に記載のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含むことを特徴とする高レバウジオシドM含有ステビア植物体を作出する方法。
- 第2の植物体が請求項1~4のいずれか一項に記載のステビア植物体である、請求項7に記載の方法。
- 請求項1~4のいずれか一項に記載の植物体、請求項5に記載の種子、組織、組織培養物又は細胞の抽出物。
- 請求項9に記載の抽出物を含む飲食品、甘味組成物、香料又は医薬品。
- 請求項1~4のいずれか一項に記載の植物体、請求項5に記載の種子、組織、組織培養物又は細胞から抽出物を得る工程を含む、レバウジオシドM含有抽出物の製造方法。
- 請求項11に記載のレバウジオシドM含有抽出物からレバウジオシドMを精製する工程を含む、レバウジオシドMの製造方法。
- 請求項11に記載の方法により得られる抽出物及び/又は請求項12に記載の方法により得られるレバウジオシドMと他の成分とを混合する工程を含む、飲食品、甘味組成物、香料又は医薬品の製造方法。
- 被験植物のゲノムから以下の(1)~(5)の少なくとも1つの遺伝的特徴の存在及び/又は不在を検出する工程を含む、高レバウジオシドM含有型ステビア植物体をスクリーニングする方法。
(1)配列番号35の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号37の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号39の41位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号42の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号43の50位に相当する位置の塩基がAであるアレルについてホモ接合性である。
- 被験植物のゲノムからP01~P05からなる群より選択される少なくとも一つの多型マーカーを検出する工程を含む、請求項14に記載の方法。
- さらに、葉組織のレバウジオシドMの含有量を測定する工程を含む、請求項14又は15に記載の方法。
- (1)配列番号1における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号2における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(2)配列番号3における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号4における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(3)配列番号5における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号6における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(4)配列番号7における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号8における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、あるいは
(5)配列番号9における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号10における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
からなる群より選択されるいずれか一つ以上のプライマーセットであり、前記任意の連続する15塩基以上の配列は各プライマーの3‘末端に位置する、前記プライマーセット。 - 請求項17に記載のプライマーセットと、場合により制限酵素とを含むキットであり、
前記プライマーセットが配列番号1における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素XbaIを含み、
前記プライマーセットが配列番号3における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素KpnIを含み、
前記プライマーセットが配列番号5における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素AflIIを含み、
前記プライマーセットが配列番号9における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、制限酵素PvuIを含む、
前記キット。 - 検出可能な標識と結合していてもよい、配列番号55~64のいずれか一つに示す塩基配列を含むプローブ。
- 蛍光標識、色素又は結合部分を有する請求項19に記載のプローブ。
- P01~P05からなる群より選択される少なくとも一つの多型マーカーを検出することを目的として被験植物のゲノムDNAに対し請求項17に記載のプライマーセットを用いてPCR増幅を行う工程、及び前記多型マーカーがP01~P03及びP05からなる群より選択される少なくとも一つである場合、前記PCR増幅により得られたPCR産物を制限酵素で処理し、制限酵素処理産物を検出する工程を含む、高レバウジオシドM含有非遺伝子組み換えステビア植物体のスクリーニング方法。
- 前記制限酵素がXbaI、KpnI、AflII及びPvuIからなる群より選択される少なくとも一つである、請求項21に記載の方法。
- 前記多型マーカーがP02及びP05を含む、請求項21に記載の方法。
- 前記制限酵素がKpnI及びPvuIを含む、請求項23に記載の方法。
- スクリーニングにより得られる植物体が葉に含まれる総ステビオール配糖体量に対し2%以上のレバウジオシドMを含む、請求項21~24のいずれか一項に記載の方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18866807.3A EP3695714A4 (en) | 2017-10-12 | 2018-10-12 | REBAUDIOSIDE M RICH STEVIA PLANT |
CN201880064767.7A CN111163631A (zh) | 2017-10-12 | 2018-10-12 | 富含瑞鲍迪苷m的甜菊植物 |
AU2018350050A AU2018350050A1 (en) | 2017-10-12 | 2018-10-12 | Rebaudioside M-rich stevia plant |
JP2019548252A JPWO2019074089A1 (ja) | 2017-10-12 | 2018-10-12 | 高レバウジオシドm含有ステビア植物 |
US16/754,621 US20200281141A1 (en) | 2017-10-12 | 2018-10-12 | Rebaudioside m-rich stevia plant |
BR112020006485-8A BR112020006485A2 (pt) | 2017-10-12 | 2018-10-12 | planta de estévia, semente, um tecido, uma cultura de tecido ou uma célula de planta cultivada, métodos para produzir uma planta de estévia, um extrato contendo rebaudiosídeo m, rebaudiosídeo m, um produto alimentício ou de beber, uma composição adoçante, um sabor ou um medicamento e para selecionar uma planta de estévia, extrato da planta, produto alimentício ou de beber, uma composição adoçante, um sabor ou um medicamento, qualquer um ou mais conjunto(s) do oligonucleotídeo iniciador, kit, e, sonda |
JP2023038830A JP2023075257A (ja) | 2017-10-12 | 2023-03-13 | 高レバウジオシドm含有ステビア植物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017198515 | 2017-10-12 | ||
JP2017-198515 | 2017-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019074089A1 true WO2019074089A1 (ja) | 2019-04-18 |
Family
ID=66101618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/038064 WO2019074089A1 (ja) | 2017-10-12 | 2018-10-12 | 高レバウジオシドm含有ステビア植物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200281141A1 (ja) |
EP (1) | EP3695714A4 (ja) |
JP (2) | JPWO2019074089A1 (ja) |
CN (1) | CN111163631A (ja) |
AR (1) | AR113768A1 (ja) |
AU (1) | AU2018350050A1 (ja) |
BR (1) | BR112020006485A2 (ja) |
WO (1) | WO2019074089A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020027155A1 (ja) * | 2018-07-31 | 2020-02-06 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
WO2020138364A1 (ja) * | 2018-12-28 | 2020-07-02 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
WO2020209265A1 (ja) * | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花芽形成能の低いステビア植物 |
WO2020209266A1 (ja) * | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花粉形成能の低いステビア植物 |
WO2021061805A1 (en) * | 2019-09-24 | 2021-04-01 | Purecircle Usa Inc. | Stevia cultivar '320032' with super high rebaudioside a content |
WO2021085643A1 (ja) | 2019-11-01 | 2021-05-06 | サントリーホールディングス株式会社 | レバウディオサイドd含有晶析物の製造方法およびレバウディオサイドd含有晶析物 |
WO2021085644A1 (ja) | 2019-11-01 | 2021-05-06 | サントリーホールディングス株式会社 | レバウディオサイドd含有晶析物の製造方法およびレバウディオサイドd含有晶析物 |
WO2021084325A1 (en) * | 2019-11-01 | 2021-05-06 | Purecircle Usa, Inc. | Stevia cultivar '18136109' |
WO2021230258A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高レバウジオシドe含有ステビア植物体 |
WO2021230259A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高ステビオール配糖体含有ステビア植物及びそのスクリーニング方法 |
WO2021230257A1 (ja) | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | レバウジオシドm含有比の高いステビア植物及びそのスクリーニング方法 |
WO2021230256A1 (ja) | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
CN114173555A (zh) * | 2019-07-31 | 2022-03-11 | 三得利控股株式会社 | 含有新型甜菊醇糖苷的植物体 |
WO2024005142A1 (ja) * | 2022-06-30 | 2024-01-04 | サントリーホールディングス株式会社 | ステビア植物のスクリーニング方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113229136B (zh) * | 2021-05-25 | 2022-02-11 | 南京农业大学 | 一种甜叶菊叶片品质育种亲本选配方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
JP2009517043A (ja) | 2005-11-23 | 2009-04-30 | ザ・コカ−コーラ・カンパニー | ビタミンを含む高甘味度甘味料組成物及びこれにより甘味を付与された組成物 |
WO2010038911A1 (en) | 2008-10-03 | 2010-04-08 | Morita Kagaku Kogyo Co., Ltd. | New steviol glycoside |
US20160057955A1 (en) | 2014-09-02 | 2016-03-03 | Purecircle Sdn Bhd | Stevia Cultivar '817096' |
WO2016049531A1 (en) * | 2014-09-26 | 2016-03-31 | Purecircle Usa Inc. | Single nucleotide polymorphism (snp) markers for stevia |
JP2016515814A (ja) | 2013-03-15 | 2016-06-02 | カーギル・インコーポレイテッド | 増大したレバウジオシドd含量を有するステビア属植物 |
WO2017171023A1 (ja) * | 2016-03-31 | 2017-10-05 | サントリーホールディングス株式会社 | ヘスペリジンの沈殿が抑制された飲料 |
JP2017198515A (ja) | 2016-04-27 | 2017-11-02 | パナソニックIpマネジメント株式会社 | 磁気センサこれを用いた回転検出装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104151378A (zh) * | 2014-08-12 | 2014-11-19 | 济南汉定生物工程有限公司 | 一种甜菊糖甙rm的提纯方法 |
-
2018
- 2018-10-12 CN CN201880064767.7A patent/CN111163631A/zh active Pending
- 2018-10-12 AU AU2018350050A patent/AU2018350050A1/en active Pending
- 2018-10-12 WO PCT/JP2018/038064 patent/WO2019074089A1/ja unknown
- 2018-10-12 AR ARP180102991A patent/AR113768A1/es unknown
- 2018-10-12 BR BR112020006485-8A patent/BR112020006485A2/pt unknown
- 2018-10-12 EP EP18866807.3A patent/EP3695714A4/en active Pending
- 2018-10-12 US US16/754,621 patent/US20200281141A1/en active Pending
- 2018-10-12 JP JP2019548252A patent/JPWO2019074089A1/ja active Pending
-
2023
- 2023-03-13 JP JP2023038830A patent/JP2023075257A/ja active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
JP2009517043A (ja) | 2005-11-23 | 2009-04-30 | ザ・コカ−コーラ・カンパニー | ビタミンを含む高甘味度甘味料組成物及びこれにより甘味を付与された組成物 |
WO2010038911A1 (en) | 2008-10-03 | 2010-04-08 | Morita Kagaku Kogyo Co., Ltd. | New steviol glycoside |
JP2012504552A (ja) | 2008-10-03 | 2012-02-23 | 守田化学工業株式会社 | 新規ステビオール配糖体 |
JP2016515814A (ja) | 2013-03-15 | 2016-06-02 | カーギル・インコーポレイテッド | 増大したレバウジオシドd含量を有するステビア属植物 |
US20160057955A1 (en) | 2014-09-02 | 2016-03-03 | Purecircle Sdn Bhd | Stevia Cultivar '817096' |
WO2016049531A1 (en) * | 2014-09-26 | 2016-03-31 | Purecircle Usa Inc. | Single nucleotide polymorphism (snp) markers for stevia |
WO2017171023A1 (ja) * | 2016-03-31 | 2017-10-05 | サントリーホールディングス株式会社 | ヘスペリジンの沈殿が抑制された飲料 |
JP2017198515A (ja) | 2016-04-27 | 2017-11-02 | パナソニックIpマネジメント株式会社 | 磁気センサこれを用いた回転検出装置 |
Non-Patent Citations (7)
Title |
---|
"Protocols for In Vitro cultures and secondary metabolite analysis of aromatic and medicinal plants", METHOD IN MOLECULAR BIOLOGY, vol. 1391, pages 113 - 123 |
LIVAK, K. J., BIOMOL. ENG., vol. 14, 1999, pages 143 - 149 |
LIVAK, K. J., GENET). ANAL., vol. 14, 1999, pages 143 |
LYAMICHEV, V. ET AL., SCIENCE, vol. 260, 1993, pages 778 - 783 |
MORRIS T. ET AL., J. CLIN. MICROBIOL., vol. 34, 1996, pages 2933 |
OHTA ET AL., J. APPL. GLYCOSCI., vol. 57, no. 3, 2010 |
SAMBROOKFRITSCHMANIATIS: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11732313B2 (en) | 2018-07-31 | 2023-08-22 | Suntory Holdings Limited | High-sweetening-content stevia plant and method for screening same |
WO2020027155A1 (ja) * | 2018-07-31 | 2020-02-06 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
WO2020138364A1 (ja) * | 2018-12-28 | 2020-07-02 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
JP7520722B2 (ja) | 2018-12-28 | 2024-07-23 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
JPWO2020138364A1 (ja) * | 2018-12-28 | 2021-11-04 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
WO2020209265A1 (ja) * | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花芽形成能の低いステビア植物 |
WO2020209266A1 (ja) * | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花粉形成能の低いステビア植物 |
CN114173555A (zh) * | 2019-07-31 | 2022-03-11 | 三得利控股株式会社 | 含有新型甜菊醇糖苷的植物体 |
WO2021061805A1 (en) * | 2019-09-24 | 2021-04-01 | Purecircle Usa Inc. | Stevia cultivar '320032' with super high rebaudioside a content |
CN114929013B (zh) * | 2019-09-24 | 2024-05-14 | 谱赛科美国股份有限公司 | 具有超高莱鲍迪苷a含量的甜菊栽培品种‘320032’ |
CN114929013A (zh) * | 2019-09-24 | 2022-08-19 | 谱赛科美国股份有限公司 | 具有超高莱鲍迪苷a含量的甜菊栽培品种‘320032’ |
CN115087347A (zh) * | 2019-11-01 | 2022-09-20 | 谱赛科美国股份有限公司 | 甜菊栽培品种‘18136109’ |
WO2021084325A1 (en) * | 2019-11-01 | 2021-05-06 | Purecircle Usa, Inc. | Stevia cultivar '18136109' |
WO2021085644A1 (ja) | 2019-11-01 | 2021-05-06 | サントリーホールディングス株式会社 | レバウディオサイドd含有晶析物の製造方法およびレバウディオサイドd含有晶析物 |
CN115087347B (zh) * | 2019-11-01 | 2024-05-17 | 谱赛科美国股份有限公司 | 甜菊栽培品种‘18136109’ |
WO2021085643A1 (ja) | 2019-11-01 | 2021-05-06 | サントリーホールディングス株式会社 | レバウディオサイドd含有晶析物の製造方法およびレバウディオサイドd含有晶析物 |
WO2021230256A1 (ja) | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
WO2021230257A1 (ja) | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | レバウジオシドm含有比の高いステビア植物及びそのスクリーニング方法 |
WO2021230259A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高ステビオール配糖体含有ステビア植物及びそのスクリーニング方法 |
WO2021230258A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高レバウジオシドe含有ステビア植物体 |
EP4151743A1 (en) * | 2020-05-12 | 2023-03-22 | Suntory Holdings Limited | Stevia plant having high rebaudioside m content ratio and screening method for same |
EP4151743A4 (en) * | 2020-05-12 | 2024-05-29 | Suntory Holdings Limited | STEVIA PLANT WITH HIGH REBAUDOSIDE M CONTENT AND ITS SCREENING METHOD |
WO2024005142A1 (ja) * | 2022-06-30 | 2024-01-04 | サントリーホールディングス株式会社 | ステビア植物のスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
AR113768A1 (es) | 2020-06-10 |
JP2023075257A (ja) | 2023-05-30 |
US20200281141A1 (en) | 2020-09-10 |
JPWO2019074089A1 (ja) | 2020-11-26 |
AU2018350050A1 (en) | 2020-04-02 |
BR112020006485A2 (pt) | 2020-10-13 |
EP3695714A4 (en) | 2021-07-21 |
EP3695714A1 (en) | 2020-08-19 |
CN111163631A (zh) | 2020-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019074089A1 (ja) | 高レバウジオシドm含有ステビア植物 | |
JP7337068B2 (ja) | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 | |
US20230225273A1 (en) | Stevia plant having high rebaudioside m content ratio and screening method for same | |
JP7520722B2 (ja) | 高レバウジオシドd含有ステビア植物 | |
JP2024012453A (ja) | チラミン低含有ステビア植物 | |
JP7564803B2 (ja) | 花粉形成能の低いステビア植物 | |
US20230172136A1 (en) | Rebaudioside d-rich stevia plant | |
WO2020209265A1 (ja) | 花芽形成能の低いステビア植物 | |
EP4151082A1 (en) | High steviol glycoside-containing stevia plant and method for screening same | |
EP4151083A1 (en) | Stevia plant with high content of rebaudioside e |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18866807 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019548252 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018350050 Country of ref document: AU Date of ref document: 20181012 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018866807 Country of ref document: EP Effective date: 20200512 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020006485 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020006485 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200331 |